WO2015025967A1 - 網膜組織及び網膜関連細胞の製造方法 - Google Patents
網膜組織及び網膜関連細胞の製造方法 Download PDFInfo
- Publication number
- WO2015025967A1 WO2015025967A1 PCT/JP2014/072065 JP2014072065W WO2015025967A1 WO 2015025967 A1 WO2015025967 A1 WO 2015025967A1 JP 2014072065 W JP2014072065 W JP 2014072065W WO 2015025967 A1 WO2015025967 A1 WO 2015025967A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- retinal
- serum
- medium
- signaling pathway
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
- C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/19—Growth and differentiation factors [GDF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Definitions
- the present invention relates to a method for producing retinal tissue and retinal related cells such as retinal progenitor cells and retinal layer-specific neurons.
- a method for producing a three-dimensional retinal tissue from pluripotent stem cells uniform pluripotent stem cell aggregates are formed in a serum-free medium, and this is cultured in suspension in the presence of a basement membrane preparation, and then organs
- a method of obtaining multi-layered retinal tissue by suspension culture in a culture solution Non-patent Documents 1 and 1), and uniform pluripotent stem cell aggregates in a serum-free medium containing a Wnt signal pathway inhibitor
- a method (Non-patent Document 2 and Patent Document 2) for forming a multi-layered retinal tissue by forming a suspension culture in the presence of a basement membrane preparation and then performing a suspension culture in a serum medium is shown. .
- the present invention provides a method for producing retinal tissue and retinal related cells such as retinal progenitor cells and retinal layer-specific neurons from pluripotent stem cells. That is, the present invention provides: [1] (1) A first step in which pluripotent stem cells are suspended in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) the aggregate formed in step (1) A retinal progenitor comprising a second step of suspension-cultured in a serum-free medium or serum medium containing no BMP signaling pathway activator without a sonic hedgehog signaling pathway activator to obtain an aggregate comprising retinal progenitor cells A method for producing cells (hereinafter sometimes referred to as the production method 1 of the present invention); [2] (1) a first step of forming an aggregate of pluripotent stem cells by suspension culture of pluripotent stem cells in a serum-free medium; (2) The aggregates formed in the step (1) are suspended in a serum-free medium or serum medium containing no BMP signaling pathway activator but no sonic
- a method for producing a retinal tissue comprising a third step of obtaining an aggregate containing a retinal tissue and substantially free of head non-neuronal ectoderm (hereinafter referred to as the present invention) May be referred to as invention production method 2); [3] (1) a first step of forming an aggregate of pluripotent stem cells by suspension culture of pluripotent stem cells in a serum-free medium; (2) The aggregates formed in the step (1) are suspended in a serum-free medium or serum medium containing no BMP signaling pathway activator but no sonic hedgehog signaling pathway activator, and retinal progenitor cells And (3) the aggregate obtained in the step (2) is any one of a sonic hedgehog signaling pathway agonist, a BMP signaling pathway agonist and a Wnt signaling pathway agonist.
- a method for producing a retinal layer-specific neuron cell comprising a third step for obtaining an aggregate substantially free of ectoderm (hereinafter also referred to as production method 3 of the present invention); [4] The production method according to any one of [1] to [3], wherein the pluripotent stem cell is a primate pluripotent stem cell; [5] The production method according to any one of [1] to [4], wherein the pluripotent stem cell is a human pluripotent stem cell; [6] The production method according to any one of [1] to [5], wherein the step (1) and the step (2) are performed in the presence of a serum substitute; [7] The production method according to any one of [1] to [6], wherein the suspension culture is performed in the absence of a basement membrane preparation;
- a reagent for evaluating toxicity / drug efficacy comprising retinal progenitor cells, retinal tissue or retinal layer-specific nerve cells produced by the method according to any one of [1] to [9]; [11] A test substance is brought into contact with a retinal progenitor cell, retinal tissue or retinal layer-specific nerve cell produced by the method according to any one of [1] to [9], and the substance is the cell or the retinal layer.
- a method for evaluating the toxicity and efficacy of the substance including testing the influence on the tissue; [12] Treatment of a disease based on a disorder of retinal tissue, comprising retinal progenitor cells, retinal tissue or retinal layer-specific nerve cells produced by the method according to any one of [1] to [9] Agent; [13] An effective amount of retinal progenitor cells, retinal tissue or retinal layer-specific nerve cells produced by the method according to any one of [1] to [9] is transplanted into a subject in need of transplantation.
- a method for treating a disease based on a disorder of retinal tissue and [14] a method according to any one of [1] to [9] for use in treating a disease based on a disorder of retinal tissue Retinal progenitor cells, retinal tissue or retinal layer-specific neurons; Etc.
- retinal progenitor cells, retinal tissue or retinal layer-specific nerve cells can be produced with high efficiency.
- a retinal progenitor cell, a retinal tissue or a retinal layer-specific nerve is cultured without adding a basement membrane preparation to the medium, that is, in the absence of a basement membrane preparation. Since cells can be obtained, the risk of contamination of heterogeneous components into the resulting cells or tissues is reduced.
- FIG. 1 shows a bright-field image (A) and a fluorescence image on the 18th day from the start of suspension culture of an RAX :: GFP knock-in human embryonic stem cell-derived aggregate cultured in suspension without adding a BMP signaling pathway agent to the medium ( B) Bright field image on the 18th day of suspension culture of the RAX :: GFP knock-in human embryonic stem cell-derived aggregate that was added to the culture medium at a concentration of 100 ng / ml on the 3rd day from the beginning of suspension culture and suspended.
- BMP4 was added to the medium to 1.5 nM on the third day from the start of suspension culture, and suspension culture of the RAX :: GFP knock-in human embryonic stem cell-derived aggregate was started on the 18th day.
- Bright field image (E) and fluorescence image (F) of eyes, and RAX GFP knock-in human embryonic stem cell-derived aggregates added to the medium so that BMP7 would be 100 ng / ml on the third day of suspension culture
- Bright field image (G) and fluorescence on the 18th day from the start of suspension culture (H) and the light on the 18th day from the start of the suspension culture of the RAX GFP knock-in human embryonic stem cell-derived aggregate that was added to the medium so that GDF7 was 100 ng / ml on the third day from the beginning of suspension culture.
- FIG. 2 shows a bright field image (A) and a fluorescence image of the RAX :: GFP knock-in human embryonic stem cell-derived aggregates cultured in suspension without adding a BMP signal transduction pathway agent to the culture medium on the 26th day.
- FIG. 6 is a bright field image (M), a fluorescence image (N), and a FACS histogram (O) on the 26th day from the start of suspension culture of RAX :: GFP knock-in human embryonic stem cell-derived aggregates added to the culture medium and suspended in suspension.
- M bright field image
- N fluorescence image
- O FACS histogram
- FIG. 3 shows a bright field image (A) and a fluorescence image on the 24th day from the start of suspension culture of RAX :: GFP knock-in human embryonic stem cell-derived aggregates cultured in suspension without adding a BMP4 signal transduction pathway agonist to the medium
- B Bright field image of the 24th day from the start of suspension culture of the RAX :: GFP knock-in human embryonic stem cell-derived aggregate that was suspended in culture by adding BMP4 to 1.5 nM on the 6th day.
- Bright field image (E) and fluorescence image (F) of eyes, RAX GFP knock-in human embryonic stem cell-derived aggregate added to BMP4 to 1.5 nM in culture medium on the 12th day from the start of suspension culture
- a bright field image (I) of the suspension culture of the RAX GFP knock-in human embryonic stem cell-derived aggregate that was suspended in culture by adding BMP4 to 1.5 nM on the 15th day.
- a fluorescent image (J) J.
- FIG. 4 shows a frozen section of a RAX :: GFP knock-in human embryonic stem cell-derived aggregate that was added to the medium so that the concentration of BMP4 was 1.5 nM on the third day of suspension culture and suspended until the beginning of suspension culture on the 26th day.
- FIG. 2 is a view showing a GFP fluorescence image (A), a fluorescence immunostaining image (B) using an anti-Chx10 antibody, and a Hoechst staining image (C).
- FIG. 5 shows a frozen section of a RAX :: GFP knock-in human embryonic stem cell-derived aggregate that was added to the medium so that BMP4 was 1.5 nM on the third day of suspension culture and suspended until the first day of suspension culture.
- FIG. 6 shows a frozen section of an aggregate of RAX :: GFP knock-in human embryonic stem cells derived by adding BMP4 to the medium at 1.5 nM on the 6th day from the start of suspension culture and suspension culture until the 50th day of suspension culture.
- Immunostaining image using anti-Chx10 antibody A
- immunostaining image using anti-Pax6 antibody B
- immunostaining image using anti-Crx antibody C
- immunostaining using anti-Brn3b antibody It is a figure which shows an image (D).
- the “vector” in the present invention means a vector capable of transferring a target polynucleotide sequence to a target cell.
- examples of such vectors include vectors capable of autonomous replication in host cells such as prokaryotic cells, yeast, animal cells, plant cells, insect cells, animal individuals or plant individuals, and integration into the host cell chromosome.
- Possible vectors, vectors containing a promoter in a position suitable for polynucleotide transcription, and the like can be mentioned.
- a vector suitable for cloning may be referred to as a “cloning vector”.
- a cloning vector a vector containing a multiple cloning site usually containing a plurality of restriction enzyme sites can be mentioned. For example, “Molecular Cloning (3rd edition)” by Sambrook, J and Russell, DW, Appendix 3 (Volume 3) Vectors and Bacterial strains. A3.2 (Cold Spring Harbor USA, 2001)).
- “vector” also includes “expression vector” and “reporter vector”.
- various regulatory elements may be linked to the “expression vector” in a state in which various regulatory elements can operate in the host cell.
- various regulatory elements may be ligated to the “reporter vector” in a state where they can operate in the host cell. Examples of the “regulatory element” include a terminator or an enhancer.
- the “expression vector” and “reporter vector” may further include a selection marker gene such as a drug resistance gene.
- cloning vector examples include (a) a lambda FIX vector that is a phage vector for the preparation of a genomic library, (b) a lambda ZAP vector that is a phage vector for the preparation of a cDNA library, ( c) In order to clone genomic DNA, plasmid vectors such as pBluescript II SK +/-, pGEM, or pCR2.1 vector can be mentioned.
- Examples of the “expression vector” include pSV2 / neo vector, pcDNA vector, pUC18 vector, pUC19 vector, pRc / RSV vector, pLenti6 / V5-Dest vector, pAd / CMV / V5-DEST vector, pDON-AI-2 /
- a plasmid vector such as neo vector or pMEI-5 / neo vector can be mentioned.
- reporter vector examples include pGL2 vector, pGL3 vector, pGL4.10 vector, pGL4.11 vector, pGL4.12 vector, pGL4.70 vector, pGL4.71 vector, pGL4.72 vector, pSLG vector, pSLO vector. , PSLR vector, pEGFP vector, pAcGFP vector, or pDsRed vector. Such vectors may be appropriately used with reference to the aforementioned Molecular Cloning magazine.
- Examples of techniques for introducing nucleic acid molecules into cells include transformation, transduction, transfection, and the like. Such introduction techniques include, for example, Ausubel F. A. et al. (1988), Current Protocols in Molecular Biology, Wiley, New York, NY; Sambrook J. et al. (1987) Molecular Cloning: A Laboratory Manual, 2nd Ed ., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Sambrook J. et al.
- “Floating culture” in the present invention means culturing under conditions that do not allow cells or cell masses to adhere to culture equipment or the like.
- the incubator used for the suspension culture is not particularly limited as long as it can perform “suspension culture” and can be appropriately determined by those skilled in the art. Examples of such incubators include flasks, tissue culture flasks, dishes, petri dishes, tissue culture dishes, multi dishes, micro plates, micro well plates, micro pores, multi plates, multi well plates, chamber slides, A petri dish, a tube, a tray, a culture bag, or a roller bottle is mentioned.
- These incubators are preferably non-cell-adhesive in order to enable suspension culture.
- the non-cell-adhesive incubator those in which the surface of the incubator has not been artificially treated (for example, coating treatment with an extracellular matrix or the like) for the purpose of improving adhesion to cells can be used.
- the medium used for cell culture can be prepared using a medium usually used for animal cell culture as a basal medium.
- a basal medium for example, BME medium, BGJb medium, CMRL 1066 medium, Glasgow MEM medium, Improved MEM Zinc Option medium, IMDM medium, Medium 199 medium, Eagle MEM medium, ⁇ MEM medium, DMEM medium, F-12 medium, Ham Examples thereof include a medium that can be used for culturing animal cells, such as a medium, an RPMI 1640 medium, a Fischer's medium, or a mixed medium thereof.
- serum-free medium means a medium that does not contain unconditioned or unpurified serum.
- a medium containing purified blood-derived components or animal tissue-derived components is also included in the serum-free medium unless it contains unconditioned or unpurified serum.
- the serum-free medium may contain a serum replacement.
- serum substitutes include those containing albumin, transferrin, fatty acid, collagen precursor, trace elements, 2-mercaptoethanol or 3 ′ thiolglycerol, or their equivalents as appropriate.
- Such a serum replacement can be prepared, for example, by the method described in WO98 / 30679.
- a commercially available product may be used as a serum substitute.
- examples of such commercially available serum substitutes include Knockout TM Serum Replacement (manufactured by Invitrogen: hereinafter referred to as KSR), Chemically defined lipid concentrate (manufactured by Gibco), and Glutamax TM (Gibco). It is done.
- the serum-free medium used for suspension culture contains fatty acids or lipids, amino acids (eg, non-essential amino acids), vitamins, growth factors, cytokines, antioxidants, 2-mercaptoethanol, pyruvic acid, buffers, inorganic salts, and the like. May be.
- a serum-free medium for example, F-12 medium and IMDM medium 1: 1 to which an appropriate amount of commercially available KSR is added (for example, about 1% to about 20%) is added.
- KSR commercially available KSR
- a medium in which 10% KSR and 450 ⁇ M 1-monothioglycerol are added to one mixed solution may be used.
- serum medium means a medium containing unadjusted or unpurified serum.
- the medium contains fatty acids or lipids, amino acids (eg, non-essential amino acids), vitamins, growth factors, cytokines, antioxidants, 2-mercaptoethanol, 1-monothioglycerol, pyruvic acid, buffers, inorganic salts, etc. May be.
- the “basement membrane preparation” refers to epithelial cell-like cell morphology, differentiation, proliferation, motility, functional expression, etc. when seeded with desired cells having the ability to form a basement membrane. It includes a basement membrane component having a function of controlling.
- the “basement membrane component” refers to a thin membrane-like extracellular matrix molecule that exists between an epithelial cell layer and a stromal cell layer in an animal tissue.
- a basement membrane preparation removes cells having a basement membrane-forming ability adhered to a support through a basement membrane from the support using a solution or an alkaline solution having lipid-dissolving ability of the cells. Can be produced.
- Basement membrane preparations include products that are commercially available as basement membrane preparations (for example, Matrigel TM (manufactured by Becton Dickinson: hereinafter, sometimes referred to as Matrigel)), and known extracellular matrix as a basement membrane component. Examples include molecules (for example, laminin, type IV collagen, heparan sulfate proteoglycan, entactin, etc.). Matrigel TM is a basement membrane preparation extracted from Engelbreth Holm Swarm (EHS) mouse sarcoma.
- EHS Engelbreth Holm Swarm
- Matrigel TM The main components of Matrigel TM are type IV collagen, laminin, heparan sulfate proteoglycan and entactin, in addition to these naturally produced by TGF- ⁇ , fibroblast growth factor (FGF), tissue plasminogen activator and EHS tumor Growth factors are included.
- Matrigel TM “growth factor reduced products” have lower concentrations of growth factors than normal Matrigel TM , with standard concentrations of EGF ⁇ 0.5 ng / ml, NGF ⁇ 0.2 ng / ml, PDGF ⁇ 5 pg / ml, IGF-1 at 5 ng / ml, and TGF- ⁇ at 1.7 ng / ml.
- medium containing substance X means a medium to which exogenous substance X is added or a medium containing exogenous substance X
- medium not containing substance X Means a medium to which no exogenous substance X is added or a medium not containing exogenous substance X.
- exogenous substance X means substance X that is foreign to cells or tissues cultured in the medium, and includes endogenous substance X produced by the cells or tissues. I can't.
- the “medium containing a BMP signal transduction pathway agent” is a medium supplemented with an exogenous BMP signal transduction pathway agent or a medium containing an exogenous BMP signal transduction pathway agent.
- Sonic hedgehog signaling pathway agent-free medium refers to a medium to which exogenous sonic hedgehog signaling pathway agent is not added or exogenous sonic hedgehog signaling pathway agonist The medium does not contain.
- primary refers to mammals belonging to the order of primates, and examples of primates include wild monkeys such as lemurs, loris and camellia, and monkeys such as monkeys, apes and humans.
- the “stem cell” in the present invention is a cell that maintains the same differentiation ability even after cell division, and can contribute to regeneration of the tissue when the tissue is damaged.
- Stem cells include embryonic stem cells (hereinafter also referred to as ES cells) or tissue stem cells (also called tissue stem cells, tissue-specific stem cells or somatic stem cells), or induced pluripotent stem cells (iPS cells: induced) pluripotent stem cell). It is known that the above stem cell-derived tissue cells can be differentiated into normal cells close to a living body, as can be seen from the fact that tissue regeneration is possible. Stem cells can be obtained from a predetermined institution, and commercially available products can also be purchased.
- human embryonic stem cells KhES-1, KhES-2, and KhES-3 are available from the Institute of Regenerative Medicine, Kyoto University.
- EB5 cells both mouse embryonic stem cells, are available from RIKEN, and the D3 strain is available from ATCC.
- Stem cells can be maintained and cultured by a method known per se.
- human stem cells can be maintained by culturing in a medium supplemented with Knockout TM Serum Replacement (Invitrogen).
- Mouse stem cells can be maintained by adding fetal calf serum (FCS) and Leukemia Inhibitory Factor (LIF) and culturing under feeder-free conditions.
- FCS fetal calf serum
- LIF Leukemia Inhibitory Factor
- the “pluripotent stem cell” in the present invention can be cultured in vitro and all cells constituting the living body excluding the placenta (tissues derived from the three germ layers (ectoderm, mesoderm, endoderm)) Refers to a stem cell having the ability to differentiate into (pluripotency).
- Embryonic stem cells ES cells
- Pluripotent stem cells are obtained from fertilized eggs, cloned embryos, germline stem cells or stem cells in tissue. Cells that are artificially provided with pluripotency similar to embryonic stem cells by introducing several types of genes into somatic cells (also called induced pluripotent stem cells) are also included in “pluripotent stem cells”.
- Pluripotent stem cells can be prepared by a method known per se.
- a production method for example, in the case of an induced pluripotent stem cell, Cell, 2007, 131 (5) pp. 861-872, Cell, 2006, 126 (4) pp. The method described in 663-676 is mentioned.
- the “embryonic stem cell (ES cell)” in the present invention is a stem cell having self-renewal ability and pluripotency (particularly pluripotency “pluripotency”), and a pluripotent stem cell derived from an early embryo Say. Embryonic stem cells were first established in 1981, and have been applied since 1989 to the production of knockout mice. In 1998, human embryonic stem cells were established and are being used in regenerative medicine.
- the “artificial pluripotent stem cell” in the present invention means that pluripotency is achieved by directly initializing differentiated cells such as fibroblasts by expression of several kinds of genes such as Oct3 / 4, Sox2, Klf4, Myc, etc. Induced cells.
- differentiated cells such as fibroblasts
- genes such as Oct3 / 4, Sox2, Klf4, Myc, etc. Induced cells.
- Yamanaka et al. Established artificial pluripotent stem cells using mouse cells (Cell, 2006, 126 (4) pp.663-676).
- Artificial pluripotent stem cells were also established in human fibroblasts in 2007 and have differentiation pluripotency similar to embryonic stem cells (Cell, 2007, 131 (5) pp.861-872; Science, 2007, 318 (5858) pp.1917-1920; Nat. Biotechnol., 2008, 26 (1) pp. 101-106).
- a genetically modified pluripotent stem cell can be prepared, for example, by using a homologous recombination technique.
- genes on the chromosome to be modified include cell marker genes, histocompatibility antigen genes, and disease-related genes based on nervous system cell disorders. Modifications of target genes on chromosomes include Manipulating the Mouse Embryo, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Pirc. 8. Gene targeting, production of mutant mice using ES cells, Yochisha (1995); and the like.
- a genomic gene of a target gene to be modified eg, cell marker gene, histocompatibility antigen gene, disease-related gene, etc.
- the target gene is homologous using the isolated genomic gene
- a target vector for recombination is prepared.
- genomic gene of the target gene can also be isolated by using a genomic DNA library screening system (manufactured by Genome Systems) or Universal GenomeWalker Kits (manufactured by CLONTECH).
- target vectors for homologous recombination of target genes and efficient selection of homologous recombinants are described in Gene Targeting, A Practical Approach, IRL Press at Oxford University Press (1993); Biomanual Series 8, Gene Targeting , Production of mutant mice using ES cells, Yodosha (1995); and the like.
- the target vector can be either a replacement type or an insertion type.
- methods such as positive selection, promoter selection, negative selection, or poly A selection can be used. Examples of a method for selecting a target homologous recombinant from the selected cell lines include Southern hybridization method and PCR method for genomic DNA.
- the “aggregate” in the present invention refers to a mass formed by aggregation of cells dispersed in a medium.
- the “aggregate” in the present invention includes an aggregate formed by cells dispersed at the start of suspension culture and an aggregate already formed at the start of suspension culture.
- “Aggregate formation” means that when cells are aggregated to form cell aggregates and suspension culture is performed, a qualitatively uniform cell is formed by “aggregating a certain number of dispersed cells rapidly”. It means forming an aggregate.
- Experimental operations for forming aggregates include, for example, a method of confining cells in a small space using a plate with a small well (96-well plate) or a micropore, or a short centrifugation using a small centrifuge tube.
- a method of aggregating cells is mentioned.
- the formation of aggregates of pluripotent stem cells and the formation of epithelial structures in the cells forming the aggregates are microscopically determined by aggregate size and number of cells, macroscopic morphology, and tissue staining analysis. It is possible to make a judgment based on the target morphology and its uniformity, the expression and uniformity of differentiation and undifferentiation markers, the expression control and synchronization of differentiation markers, the reproducibility of the differentiation efficiency between aggregates, and the like.
- tissue in the present invention refers to a structure of a cell population having a structure in which a plurality of types of cells having different forms and properties are three-dimensionally arranged in a certain pattern.
- retinal tissue means at least cells such as photoreceptor cells, horizontal cells, bipolar cells, amacrine cells, retinal node cells, progenitor cells thereof, or retinal progenitor cells constituting each retinal layer in a living retina. It means multiple types of retinal tissues arranged in layers and three-dimensionally. Whether each cell constitutes which retinal layer can be confirmed by a known method, for example, the presence or absence of the expression of a cell marker or the degree thereof.
- the “retinal layer” in the present invention means each layer constituting the retina. Specifically, the retinal pigment epithelium layer, photoreceptor layer, outer boundary membrane, outer granular layer, outer reticulated layer, inner granular layer, inner granular layer, Mention may be made of the reticular layer, the ganglion cell layer, the nerve fiber layer and the inner limiting membrane.
- the “retinal layer-specific nerve cell” means a cell constituting the retinal layer and specific to the retinal layer.
- retinal layer-specific neurons include bipolar cells, nodal cells, amacrine cells, horizontal cells, photoreceptor cells, pigment epithelial cells, rod cells, and cone cells.
- the “retinal progenitor cell” in the present invention refers to a progenitor cell that can differentiate into any mature retinal cell of a photoreceptor cell, a horizontal cell, a bipolar cell, an amacrine cell, a retinal node cell, and a retinal pigment epithelial cell.
- Visual cell progenitor cells, horizontal cell progenitor cells, bipolar cell progenitor cells, amacrine cell progenitor cells, retinal node cell progenitor cells, and retinal pigment epithelial progenitor cells, respectively, are photoreceptor cells, horizontal cells, bipolar cells, amacrine cells, and retinal nodes.
- Cell a progenitor cell that has been determined to differentiate into retinal pigment epithelial cells.
- Rax and PAX expressed in retinal progenitor cells As retinal cell markers, Rax and PAX expressed in retinal progenitor cells, Nkx2.1 that is expressed in progenitor cells of hypothalamic neurons but not in retinal progenitor cells, Sox1 that is expressed in hypothalamic neuroepithelium but not in the retina, visual Examples include Crx expressed in cell precursor cells.
- Chx10 and L7 expressed in bipolar cells As markers for retinal layer-specific neurons, Chx10 and L7 expressed in bipolar cells, Tuj1 and Brn3 expressed in nodal cells, Calretinin expressed in amacrine cells, Calbindin expressed in horizontal cells, Rhodopsin expressed in photoreceptor cells and Recoverin, RPE65 and Mitf expressed in pigment epithelial cells, Nrl expressed in rod cells, Rxr-gamma expressed in cone cells, and the like.
- the production method 1 of the present invention is a method for producing retinal progenitor cells including the following steps (1) and (2): (1) The first step of forming pluripotent stem cell aggregates by suspension culture in a serum-free medium, and (2) the aggregates formed in step (1) The second step of obtaining an aggregate containing retinal progenitor cells by suspension culture in a serum-free medium or serum medium containing a BMP signal transduction pathway agent but not containing a hedgehog signal transduction pathway agent.
- the step (1) of forming pluripotent stem cell aggregates by suspension culture of pluripotent stem cells in a serum-free medium will be described.
- the serum-free medium used in step (1) is not particularly limited as long as it is as described above.
- a serum-free medium to which neither a BMP signal transduction pathway agonist nor a Wnt signal pathway inhibitor is added can be used.
- a serum-free medium for example, 10% KSR, 450 ⁇ M 1-mono in a 1: 1 mixture of IMDM and F-12 added with a suitable amount of a commercially available serum substitute such as KSR). It is preferable to use a medium supplemented with thioglycerol and 1 ⁇ Chemically Defined Lipid Concentrate.
- the amount of KSR added to the serum-free medium is usually about 1% to about 20%, preferably about 2% to about 20%.
- Culture conditions such as culture temperature and CO 2 concentration in the step (1) can be appropriately set.
- the culture temperature is, for example, about 30 ° C. to about 40 ° C., preferably about 37 ° C.
- the CO 2 concentration is, for example, from about 1% to about 10%, preferably about 5%.
- the concentration of pluripotent stem cells in step (1) can be appropriately set so that aggregates of pluripotent stem cells are formed more uniformly and efficiently.
- concentration of pluripotent stem cells in step (1) can be appropriately set so that aggregates of pluripotent stem cells are formed more uniformly and efficiently.
- a solution prepared to be about 5 ⁇ 10 3 to about 3 ⁇ 10 4 cells, most preferably about 1.2 ⁇ 10 4 cells is added to the well, and the plate is allowed to stand to form an aggregate. .
- the suspension culture time required to form aggregates can be determined as appropriate depending on the pluripotent stem cells used so that the cells can be aggregated uniformly, but as short as possible to form uniform aggregates. It is desirable to be time. For example, in the case of human ES cells, aggregates are preferably formed within about 24 hours, more preferably within about 12 hours. The time until the formation of the aggregates can be appropriately adjusted by adjusting tools for aggregating cells, centrifugation conditions, and the like.
- the formation of aggregates of pluripotent stem cells is due to the size and number of the aggregates, the macroscopic morphology, the microscopic morphology and its homogeneity by tissue staining analysis, the expression and the homogeneity of differentiation and undifferentiation markers It is possible to make a judgment based on the expression control of the differentiation marker and its synchrony, the reproducibility between the aggregates of the differentiation efficiency, and the like.
- the aggregate formed in the step (1) is suspended in a serum-free medium or a serum medium containing a BMP signal transduction pathway agent without containing a sonic hedgehog signal transduction pathway agent, and a coagulation containing a retinal progenitor cell.
- the step (2) for obtaining the aggregate will be described.
- the medium used in the step (2) is, for example, a serum-free medium or a serum medium to which a BMP signal transduction pathway agent is not added without adding a sonic hedgehog signal transduction pathway agonist, There is no need to add.
- the serum-free medium or serum medium used for such a medium is not particularly limited as long as it is as described above.
- a serum-free medium for example, 10% KSR, 450 ⁇ M 1-mono in a 1: 1 mixture of IMDM and F-12 added with a suitable amount of a commercially available serum substitute such as KSR. It is preferable to use a medium supplemented with thioglycerol and 1 ⁇ Chemically Defined Lipid Concentrate.
- the amount of KSR added to the serum-free medium is usually about 1% to about 20%, preferably about 2% to about 20%.
- the serum-free medium used in step (2) can be used as it is as long as the serum-free medium used in step (1) does not contain a sonic hedgehog signaling pathway agent. It can also be replaced with serum medium.
- the BMP signal transduction pathway agent may be added to the medium.
- a sonic hedgehog (hereinafter sometimes referred to as Shh) signaling pathway agent is a substance that can enhance signal transduction mediated by Shh.
- substances that act on the Shh signal transduction pathway include proteins belonging to the Hedgehog family (for example, Shh), Shh receptors, Shh receptor agonists, Purmorphamine, or SAG.
- Sonic hedgehog signaling pathway agent free media includes media that are substantially free of sonic hedgehog signaling pathway agonists, such as selective differentiation into retinal progenitor cells and retinal tissue. Also included are media that do not contain sonic hedgehog signal transduction pathway agents at concentrations that have a significant impact.
- “Sonic hedgehog signaling pathway agonist” medium is essentially free of sonic hedgehog signaling pathway agonist, eg selection for retinal progenitor cells and retinal tissue Also included is a medium to which no sonic hedgehog signaling pathway agent is added at a concentration that adversely affects sexual differentiation.
- a substance acting on a BMP signal transduction pathway is a substance that can enhance a signal transduction pathway mediated by BMP.
- substances that act on the BMP signaling pathway include BMP proteins such as BMP2, BMP4 and BMP7, GDF proteins such as GDF7, anti-BMP receptor antibodies, and BMP partial peptides.
- BMP2 protein, BMP4 protein and BMP7 protein are available from, for example, R & D Systems, and GDF7 protein is available from, for example, Wako Pure Chemical Industries.
- the concentration of the BMP signal transduction pathway agent may be any concentration that can induce differentiation of cells forming aggregates of pluripotent stem cells into retinal cells. For example, in the case of BMP4, it is added to the medium to a concentration of about 0.01 nM to about 1 ⁇ M, preferably about 0.1 nM to about 100 nM, more preferably about 1.5 nM.
- the BMP signal transduction pathway agent may be added after about 24 hours from the start of suspension culture in step (1), and may be added to the medium within several days (for example, within 15 days) after the start of suspension culture. Also good. Preferably, the BMP signal transduction pathway agent is added to the culture medium from the first day to the fifteenth day after the start of suspension culture, more preferably from the first day to the ninth day, most preferably the third day. To do. After the BMP signaling pathway agent is added to the medium and the induction of differentiation into cells that form aggregates of pluripotent stem cells is initiated, it is necessary to add the BMP signaling pathway agent to the medium. Alternatively, the medium may be changed using a serum-free medium or serum medium that does not contain a BMP signaling pathway agent.
- the aggregate formed in the step (1) is used for the BMP at a concentration necessary for inducing differentiation into a retinal cell until cells expressing the Rax gene begin to appear.
- the culture conditions such as culture temperature and CO 2 concentration in the step (2) can be appropriately set.
- the culture temperature is, for example, about 30 ° C. to about 40 ° C., preferably about 37 ° C.
- the CO 2 concentration is, for example, about 1% to about 10%, preferably about 5%.
- an aggregate containing retinal progenitor cells can be confirmed, for example, by detecting that cells expressing Rax or PAX6, which are markers for retinal progenitor cells, are contained in the aggregate.
- the obtained aggregate containing retinal progenitor cells may be used as it is as a reagent for evaluating toxicity and drug efficacy.
- High-purity retinal progenitor cells can also be obtained by dispersing aggregates containing retinal progenitor cells (for example, trypsin / EDTA treatment) and sorting the obtained cells using FACS.
- the production method 2 of the present invention is a method for producing retinal tissue including the following steps (1), (2) and (3): (1) a first step of forming pluripotent stem cell aggregates by suspension culture of pluripotent stem cells in a serum-free medium; (2) The aggregates formed in the step (1) are suspended in a serum-free medium or serum medium containing no BMP signaling pathway activator but no sonic hedgehog signaling pathway activator, and retinal progenitor cells And (3) the aggregate obtained in the step (2) is any one of a sonic hedgehog signaling pathway agonist, a BMP signaling pathway agonist and a Wnt signaling pathway agonist.
- step (1) and the step (2) of the production method 2 of the present invention can be performed in the same manner as the step (1) and the step (2) of the production method 1 of the present invention.
- the aggregate obtained in the step (2) is suspended in a serum-free medium or serum medium containing neither a sonic hedgehog signaling pathway agent, a BMP signaling pathway agonist, or a Wnt signaling pathway agonist.
- the step (3) for obtaining an aggregate containing retinal tissue and substantially free of the head non-neuronal ectoderm will be described.
- the medium used in the step (3) is, for example, a serum-free medium or a serum medium to which neither a sonic hedgehog signal transduction pathway agonist, a BMP signal transduction pathway agonist, or a Wnt signal pathway agonist is added.
- "Sonic Hedgehog Signaling Pathway Agent, BMP Signaling Pathway Agent, and Wnt Signaling Pathway Agent” contains Sonic Hedgehog Signaling Pathway Agent, BMP Signaling Pathway Agent And a medium substantially free of any of the Wnt signaling pathway agonists, for example, a sonic hedgehog signaling pathway agonist, BMP signaling pathway at a concentration that adversely affects selective differentiation into retinal tissue
- media that do not contain agents and Wnt signaling pathway agents are included.
- “Sonic hedgehog signaling pathway agonist, BMP signaling pathway agonist and Wnt signaling pathway agonist are not added" medium contains sonic hedgehog signaling pathway agonist, BMP signaling pathway Medium to which neither the agent nor the Wnt signaling pathway agonist is substantially added, for example, a sonic hedgehog signaling pathway agonist at a concentration that adversely affects selective differentiation into retinal tissue, A medium to which a BMP signaling pathway agonist and a Wnt signaling pathway agonist are not added is also included.
- the serum-free medium or serum medium used for such a medium is not particularly limited as long as it is as described above.
- a serum-free medium for example, 10% KSR, 450 ⁇ M 1-mono in a 1: 1 mixture of IMDM and F-12 added with a suitable amount of a commercially available serum substitute such as KSR. It is preferable to use a medium supplemented with thioglycerol and 1 ⁇ Chemically Defined Lipid Concentrate.
- the amount of KSR added to the serum-free medium is usually about 1% to about 20%, preferably about 2% to about 20%.
- a Wnt signal pathway agonist is a substance that can enhance signal transduction mediated by Wnt.
- Wnt signaling pathway agonists include proteins belonging to the Wnt family (eg, Wnt1, Wnt3a, Wnt7a), Wnt receptors, Wnt receptor agonists, GSK3 ⁇ inhibitors (eg, 6-Bromoindirubin-3′-oxime (BIO ), CHIR99021, Kenpaullone) and the like.
- Culture conditions such as the culture temperature, CO 2 concentration, and O 2 concentration in step (3) can be appropriately set.
- the culture temperature is, for example, about 30 ° C. to about 40 ° C., preferably about 37 ° C.
- the CO 2 concentration is, for example, from about 1% to about 10%, preferably about 5%.
- the O 2 concentration is about 18% or more, such as about 20% to about 70%, preferably about 20% to about 60%, more preferably about 20% to about 50%.
- the culture time in the step (3) is not particularly limited, but is usually 48 hours or longer, preferably 7 days or longer.
- the retinal tissue exists so as to cover the surface of the aggregate.
- the aggregate is fixed using a fixative such as a paraformaldehyde solution, a frozen section is prepared, and then it is confirmed by immunostaining that a retinal tissue having a layer structure is formed.
- retinal progenitor cells visual cells, horizontal cells, bipolar cells, amacrine cells, retinal node cells
- retinal tissue uses antibodies against the above markers expressed in these cells, It can be confirmed that a layer structure is formed by immunostaining.
- the tissue is a retinal tissue.
- a RAX positive tissue is observed, and a RAX negative tissue is present on the outside thereof. Not observed.
- retinal tissue can be obtained from human pluripotent stem cells with high efficiency. Since the retinal tissue obtained by the production method 2 of the present invention includes neurons specific to each retinal layer, photoreceptor cells, horizontal cells, bipolar cells, amacrine cells, ganglion cells, or progenitor cells thereof, etc. It is also possible to obtain cells constituting the retinal tissue. Which cells are obtained from the obtained retinal tissue can be confirmed by a method known per se, for example, expression of a cell marker. The obtained aggregate containing retinal tissue and substantially free of head non-neuronal ectoderm may be used as it is as a reagent for evaluating toxicity and drug efficacy.
- High-purity retinal tissue is obtained by dispersing (for example, trypsin / EDTA treatment) an aggregate containing retinal tissue and substantially free of non-neural ectoderm of the head, and sorting the obtained cells using FACS. It is also possible to obtain constituent cells.
- the production method 3 of the present invention is a method for producing retinal layer-specific nerve cells comprising the following steps (1), (2) and (3): (1) a first step of forming pluripotent stem cell aggregates by suspension culture of pluripotent stem cells in a serum-free medium; (2) The aggregates formed in the step (1) are suspended in a serum-free medium or serum medium containing no BMP signaling pathway activator but no sonic hedgehog signaling pathway activator, and retinal progenitor cells And (3) the aggregate obtained in the step (2) is any one of a sonic hedgehog signaling pathway agonist, a BMP signaling pathway agonist and a Wnt signaling pathway agonist.
- the suspension is cultured in suspension until the target retinal layer-specific neurons appear, and the retinal tissue contains the target retinal layer-specific neurons
- a third step for obtaining an aggregate substantially free of ectoderm In a serum-free medium or serum medium that does not contain any retinal layer-specific neurons, the suspension is cultured in suspension until the target retinal layer-specific neurons appear, and the retinal tissue contains the target retinal layer-specific neurons
- step (1) and the step (2) of the production method 3 of the present invention can be performed in the same manner as the step (1) and the step (2) of the production method 1 of the present invention.
- the aggregate obtained in the step (2) is used in a serum-free medium or serum medium containing neither a sonic hedgehog signaling pathway agent, a BMP signaling pathway agent, or a Wnt signaling pathway agonist.
- the medium used in the step (3) is, for example, a serum-free medium or a serum medium to which neither a sonic hedgehog signal transduction pathway agonist, a BMP signal transduction pathway agonist, or a Wnt signal pathway agonist is added. .
- Sonic Hedgehog Signaling Pathway Agent, BMP Signaling Pathway Agent, and Wnt Signaling Pathway Agent contains Sonic Hedgehog Signaling Pathway Agent, BMP Signaling Pathway Agent And a sonic hedgehog signaling pathway at a concentration that has a detrimental effect on selective differentiation into retinal tissue and retinal layer specific neurons, substantially free of both Wnt and Wnt signaling pathway agents Also included are agents, BMP signaling pathway agonists, and media that do not contain Wnt signaling pathway agonists.
- “Sonic hedgehog signaling pathway agonist, BMP signaling pathway agonist and Wnt signaling pathway agonist are not added” medium contains sonic hedgehog signaling pathway agonist, BMP signaling pathway Sonic hedges at concentrations that adversely affect selective differentiation into media that are substantially free of both agents and Wnt signaling pathway agents, such as retinal tissue and retinal layer-specific neurons Also included are media without added Hog signaling pathway agonists, BMP signaling pathway agonists and Wnt signaling pathway agonists.
- the serum-free medium or serum medium used for such a medium is not particularly limited as long as it is as described above.
- a serum-free medium for example, IMDM and F-
- a serum substitute such as KSR or the like commercially available in DMEM-F12 medium supplemented with 10% fetal bovine serum, N2 supplement, 100 ⁇ M taurine, 500 nM retinoic acid.
- Culture conditions such as the culture temperature, CO 2 concentration, and O 2 concentration in step (3) can be appropriately set.
- the culture temperature is, for example, about 30 ° C. to about 40 ° C., preferably about 37 ° C.
- the CO 2 concentration is, for example, from about 1% to about 10%, preferably about 5%.
- the O 2 concentration is about 18% or more, such as about 20% to about 70%, preferably about 20% to about 60%, more preferably about 20% to about 50%.
- the culture time in step (3) varies depending on the target retinal layer-specific nerve cell, and is, for example, about 7 days to about 200 days.
- retinal tissue containing retinal layer-specific nerve cells exists so as to cover the surface of the aggregate.
- Confirmation of retinal tissue is the immunostaining method after the suspension culture is completed, the aggregates are fixed using a fixative such as paraformaldehyde solution, frozen sections are prepared, and retinal tissue having a layer structure is formed. It can be confirmed by such means. Since retinal progenitor cells (visual cells, horizontal cells, bipolar cells, amacrine cells, retinal node cells) that make up each layer are different from each other, retinal tissue uses antibodies against the above markers expressed in these cells, It can be confirmed that a layer structure is formed by immunostaining.
- an immunostained image of the aggregate frozen section described above shows a RAX positive tissue. No RAX negative tissue is observed outside.
- the retinal tissue obtained by the production method 3 of the present invention includes neurons specific to each retinal layer, retinal layer-specific nerves such as photoreceptor cells, horizontal cells, bipolar cells, amacrine cells, and ganglion cells. Cells can be obtained. Which cells are obtained from the obtained retinal tissue can be confirmed by a method known per se, for example, expression of a cell marker.
- the obtained aggregate containing retinal tissue containing retinal layer-specific nerve cells and substantially free of head non-neuronal ectoderm may be used as it is as a reagent for evaluating toxicity and drug efficacy.
- Aggregates containing retinal tissue containing retinal layer-specific neurons and substantially free of non-neural ectoderm of the head are dispersed (eg, trypsin / EDTA treatment), and the resulting cells are selected using FACS By doing so, it is also possible to obtain highly pure retinal layer-specific neurons.
- the obtained retinal layer-specific neurons can be further cultured as they are or after being subjected to a dispersion treatment (for example, trypsin / EDTA treatment).
- a cell adhesive culture vessel for example, a culture vessel coated with an extracellular matrix or the like (eg, poly-D-lysine, laminin, fibronectin).
- Culture conditions such as the culture temperature, CO 2 concentration, and O 2 concentration in adhesion culture can be determined as appropriate.
- the culture may be performed in the presence of a known differentiation inducer or neurotrophic factor. Examples of such differentiation inducers and neurotrophic factors include NGF (Biochem. Biophys. Res.
- the manufactured retinal tissue and retinal layer-specific nerve cells can be confirmed by combining the presence or absence of cell marker expression as an index, if necessary. By observing the cell morphology, the obtained retinal layer-specific nerve cells can be identified. Based on such a marker expression pattern and cell morphology, desired specific cells can also be isolated.
- the retinal progenitor cells, retinal tissue or retinal layer-specific nerve cells produced by the production methods 1 to 3 of the present invention are used for screening for therapeutic agents for diseases based on disorders of retinal tissue or retinal related cells, and for cell damage caused by other causes. It can be used as a cell therapy transplant material, a disease research material, and a drug discovery material for therapeutic drugs in Japan. It can also be used for toxicity studies such as phototoxicity, toxicity tests, etc. in the evaluation of toxicity and drug efficacy of chemical substances.
- diseases based on disorders of retinal tissue or retinal-related cells include organic mercury poisoning, chloroquine retinopathy, retinitis pigmentosa, age-related macular degeneration, glaucoma, diabetic retinopathy, retinopathy of newborn, and the like. .
- the retinal progenitor cells, retinal tissue or retinal layer-specific nerve cells produced by the production methods 1 to 3 of the present invention replenish the cells or the damaged tissue itself in a cell damage state (for example, for transplantation surgery). It can be used as a retina for transplantation used for, for example.
- Example 1 Production Example of Aggregate Containing Retinal Progenitor Cells RAX : GFP knock-in human ES cells (derived from KhES-1; Cell Stem Cell, 2012, 10 (6) 771-785) were obtained from “Ueno, M. et al. PNAS 2006, 103 (25), 9554-9559 ”and cultured according to the method described in“ Watanabe, K. et al. Nat Biotech 2007, 25, 681-686 ”.
- the medium is a DMEM / F12 medium (Sigma) supplemented with 20% KSR (Knockout TM Serum Replacement; Invitrogen), 0.1 mM 2-mercaptoethanol, 2 mM L-glutamine, 1 ⁇ non-essential amino acid, 5 ng / ml bFGF.
- KSR Knowout TM Serum Replacement
- 0.1 mM 2-mercaptoethanol 2 mM L-glutamine
- 1 ⁇ non-essential amino acid 5 ng / ml bFGF.
- the cultured ES cells are monodispersed using TrypLE Express (Invitrogen), and the monodispersed ES cells are non-cell-adhesive 96-well culture plate (Sumilon Spheroid Plate, Sumitomo Bakelite Co., Ltd.)
- the suspension was suspended in 100 ⁇ l of serum-free medium so that 1.2 ⁇ 10 4 cells per well were obtained, and the suspension was cultured at 37 ° C. and 5% CO 2 .
- serum-free medium a serum-free medium prepared by adding 10% KSR, 450 ⁇ M 1-monothioglycerol, 1 ⁇ chemically defined lipid concentrate, 20 ⁇ M Y27632 to a 1: 1 mixture of F-12 medium and IMDM medium is used.
- Example 2 Retinal tissue production example 1 RAX :: GFP knock-in human ES cells (derived from KhES-1; Cell Stem Cell, 2012, 10 (6) 771-785) were designated as “Ueno, M. et al. PNAS 2006, 103 (25), 9554-9559” The cells were cultured according to the method described in Watanabe, K. et al. Nat Biotech 2007, 25, 681-686.
- the medium is a DMEM / F12 medium (Sigma) supplemented with 20% KSR (Knockout TM Serum Replacement; Invitrogen), 0.1 mM 2-mercaptoethanol, 2 mM L-glutamine, 1 ⁇ non-essential amino acid, 5 ng / ml bFGF.
- KSR Knowout TM Serum Replacement
- 0.1 mM 2-mercaptoethanol 2 mM L-glutamine
- 1 ⁇ non-essential amino acid 5 ng / ml bFGF.
- the cultured ES cells are monodispersed using TrypLE Express (Invitrogen), and the monodispersed ES cells are non-cell-adhesive 96-well culture plate (Sumilon Spheroid Plate, Sumitomo Bakelite Co., Ltd.)
- the suspension was suspended in 100 ⁇ l of serum-free medium so that 1.2 ⁇ 10 4 cells per well were obtained, and the suspension was cultured at 37 ° C. and 5% CO 2 .
- serum-free medium a serum-free medium prepared by adding 10% KSR, 450 ⁇ M 1-monothioglycerol, 1 ⁇ chemically defined lipid concentrate, 20 ⁇ M Y27632 to a 1: 1 mixture of F-12 medium and IMDM medium is used.
- suspension culture is performed by adding human recombinant BMP4 (R & D) with a final concentration of 1.5 nM at any time of suspension culture start day 1, suspension culture start day 2 or suspension culture start day 3. did.
- the cells were cultured in the same manner even under conditions where no BMP signaling pathway agonist was added.
- Half of the culture medium in the well was replaced every 3 days with the above medium without the addition of BMP signaling pathway agonist.
- the aggregates were transferred from the 96-well plate to the suspension culture dish, and then 10% KSR, 450 ⁇ M 1-monothioglycerol, 1 ⁇ Chemically defined in a 1: 1 mixture of F-12 medium and IMDM medium.
- Suspension culture was performed in a serum-free medium supplemented with lipid concentrate. On the 26th day from the start of suspension culture, observation with a fluorescence microscope and measurement of the percentage of GFP positive cells by FACS were performed. It shows that retinal progenitor cells were induced under conditions where no BMP signaling pathway agonist was added (FIGS. 2A, B, C) and conditions where BMP4 was added simultaneously with the start of suspension culture (FIGS. 2D, E, F) No GFP expressing cells were observed. In comparison, either the first day of suspension culture (FIG. 2G, H, I), the second day of suspension culture (FIG. 2J, K, L), or the third day of suspension culture start (FIG.
- Example 3 Retinal tissue production example 2 RAX :: GFP knock-in human ES cells (derived from KhES-1; Cell Stem Cell, 2012, 10 (6) 771-785) were designated as “Ueno, M. et al. PNAS 2006, 103 (25), 9554-9559” The cells were cultured according to the method described in Watanabe, K. et al. Nat Biotech 2007, 25, 681-686.
- the medium is a DMEM / F12 medium (Sigma) supplemented with 20% KSR (Knockout TM Serum Replacement; Invitrogen), 0.1 mM 2-mercaptoethanol, 2 mM L-glutamine, 1 ⁇ non-essential amino acid, 5 ng / ml bFGF.
- KSR Knowout TM Serum Replacement
- 0.1 mM 2-mercaptoethanol 2 mM L-glutamine
- 1 ⁇ non-essential amino acid 5 ng / ml bFGF.
- the cultured ES cells are monodispersed using TrypLE Express (Invitrogen), and the monodispersed ES cells are non-cell-adhesive 96-well culture plate (Sumilon Spheroid Plate, Sumitomo Bakelite Co., Ltd.)
- the suspension was suspended in 100 ⁇ l of serum-free medium so that 1.2 ⁇ 10 4 cells per well were obtained, and the suspension was cultured at 37 ° C. and 5% CO 2 .
- serum-free medium a serum-free medium prepared by adding 10% KSR, 450 ⁇ M 1-monothioglycerol, 1 ⁇ chemically defined lipid concentrate, 20 ⁇ M Y27632 to a 1: 1 mixture of F-12 medium and IMDM medium is used.
- Example 4 Retinal tissue production example 3
- the aggregate containing the GFP-expressing cells obtained in Example 1 was transferred from the 96-well plate to the suspension culture dish on the 18th day from the start of suspension culture, followed by 1: 1 mixing of F-12 medium and IMDM medium.
- Suspension culture was carried out in a medium in which 10% KSR, 450 ⁇ M 1-monothioglycerol and 1 ⁇ Chemically defined lipid concentrate were added to the solution.
- the aggregates were fixed with a 4% paraformaldehyde solution, frozen sections were prepared, and the tissue structure was confirmed by immunostaining.
- RAX GFP positive and the outer layer was Chx10 positive, which is a marker for retinal stem cells (FIGS. 4A, B, C).
- RAX GFP positive epithelium
- the retinal tissue can be produced from human ES cells with high efficiency by the production method of the present invention.
- Example 5 Example of production of retinal layer-specific neurons RAX :: GFP knock-in human ES cells (derived from KhES-1; Cell Stem Cell, 2012, 10 (6) 771-785) were obtained from “Ueno, M. et al. PNAS 2006, 103 (25), 9554-9559 ”and cultured according to the method described in“ Watanabe, K. et al. Nat Biotech 2007, 25, 681-686 ”.
- the medium is a DMEM / F12 medium (Sigma) supplemented with 20% KSR (Knockout TM Serum Replacement; Invitrogen), 0.1 mM 2-mercaptoethanol, 2 mM L-glutamine, 1 ⁇ non-essential amino acid, 5 ng / ml bFGF.
- KSR Knowout TM Serum Replacement
- 0.1 mM 2-mercaptoethanol 2 mM L-glutamine
- 1 ⁇ non-essential amino acid 5 ng / ml bFGF.
- the cultured ES cells are monodispersed using TrypLE Express (Invitrogen), and the monodispersed ES cells are non-cell-adhesive 96-well culture plate (Sumilon Spheroid Plate, Sumitomo Bakelite Co., Ltd.)
- the suspension was suspended in 100 ⁇ l of serum-free medium so that 1.2 ⁇ 10 4 cells per well were obtained, and the suspension was cultured at 37 ° C. and 5% CO 2 .
- serum-free medium a serum-free medium prepared by adding 10% KSR, 450 ⁇ M 1-monothioglycerol, 1 ⁇ chemically defined lipid concentrate, 20 ⁇ M Y27632 to a 1: 1 mixture of F-12 medium and IMDM medium is used.
- Example 6 Example of production of retinal layer-specific nerve cells RAX :: GFP knock-in human ES cells (derived from KhES-1; Cell Stem Cell, 2012, 10 (6) 771-785) were prepared as "Ueno, M. et al PNAS 2006, 103 (25), 9554-9559 ”and cultured according to the method described in“ Watanabe, K. et al. Nat Biotech 2007, 25, 681-686 ”.
- the medium is a DMEM / F12 medium (Sigma) supplemented with 20% KSR (Knockout TM Serum Replacement; Invitrogen), 0.1 mM 2-mercaptoethanol, 2 mM L-glutamine, 1 ⁇ non-essential amino acid, 8 ng / ml bFGF.
- KSR Knowout TM Serum Replacement; Invitrogen
- 0.1 mM 2-mercaptoethanol 2 mM L-glutamine
- 1 ⁇ non-essential amino acid 8 ng / ml bFGF.
- the cultured ES cells are monodispersed using TrypLE Express (Invitrogen), and the monodispersed ES cells are non-cell-adhesive 96-well culture plate (Sumilon Spheroid Plate, Sumitomo Bakelite Co., Ltd.)
- the suspension was suspended in 100 ⁇ l of serum-free medium so that 1.2 ⁇ 10 4 cells per well were obtained, and the suspension was cultured at 37 ° C. and 5% CO 2 .
- serum-free medium a serum-free medium prepared by adding 10% KSR, 450 ⁇ M 1-monothioglycerol, 1 ⁇ chemically defined lipid concentrate, 20 ⁇ M Y27632 to a 1: 1 mixture of F-12 medium and IMDM medium is used.
- the culture after the 18th day from the start of suspension culture was carried out under 40% O 2 .
- the aggregates were fixed with a 4% paraformaldehyde solution, frozen sections were prepared, and the tissue structure was confirmed by immunostaining.
- all the layers are RAX :: GFP positive, Chx10 which is a marker of retinal progenitor cells and bipolar cells (FIG. 6A), Pax6 which is a marker of ganglion cells and nerve cells. Positive cells (FIG. 6B) were present, indicating that multi-layered retinal nerve tissue was formed.
- Example 7 Example of production of aggregates including retinal progenitor cells, retinal tissue, and retinal layer-specific neurons from induced pluripotent stem cells (iPS cells) Human iPS cell line 201B7 (RIKEN BioResource Center) Or available from iPS Academia Japan Co., Ltd.) to “Ueno, M. et al. PNAS 2006, 103 (25), 9554-9559” “Watanabe, K. et al. Nat Biotech 2007, 25, 681-686” Incubate according to the method described.
- iPS cells induced pluripotent stem cells
- the medium is a DMEM / F12 medium (Sigma) supplemented with 20% KSR (Knockout TM Serum Replacement; Invitrogen), 0.1 mM 2-mercaptoethanol, 2 mM L-glutamine, 1 ⁇ non-essential amino acid, 5 ng / ml bFGF.
- KSR Knockout TM Serum Replacement
- the cultured iPS cells were monodispersed using TrypLE Express (Invitrogen), and then 1.2 ⁇ 10 4 per well of a non-cell-adhesive 96-well culture plate (Sumilon Spheroid Plate, Sumitomo Bakelite).
- the cells are suspended in 100 ⁇ l of serum-free medium so as to become cells, and suspended in culture at 37 ° C. and 5% CO 2 .
- serum-free medium a serum-free medium obtained by adding 10% KSR, 450 ⁇ M 1-monothioglycerol, 1 ⁇ Chemically defined lipid concentrate, 20 ⁇ M Y27632 to a 1: 1 mixture of F-12 medium and IMDM medium is used. .
- retinal progenitor cell markers (Rax, Chx10) was confirmed by immunostaining. .
- the remaining aggregates are transferred from the 96-well plate to a suspension culture dish, and suspension culture is continued using a medium in which 10% fetal bovine serum, N2 supplement, 100 ⁇ M taurine, and 500 nM retinoic acid are added to DMEM-F12 medium.
- Culture after the 18th day from the start of suspension culture is performed under 40% O 2 .
- the aggregates were fixed with a 4% paraformaldehyde solution, and frozen sections were prepared.
- retinal layer-specific neurons Nrl, RXR-gamma, Recoverin, (Chx10, Calretinin, Calbindin) is confirmed.
- retinal progenitor cells as well as retinal tissue composed of various differentiated retinal layer-specific nerve cells, can be produced from human iPS cells.
- retinal progenitor cells, retinal tissue or retinal layer-specific nerve cells can be produced with high efficiency.
- the risk of contamination of heterogeneous components into the resulting cells or tissues is reduced.
- the production method of the present invention efficiently produces a cell group (photocell, optic nerve, etc.) constituting a retinal tissue for the purpose of evaluating toxicity and drug efficacy of a chemical substance, cell therapy, etc., and a retina having a tissue structure.
- Very useful from the viewpoint of efficiently producing retinal tissue which is a "tissue material" for use in testing and treatment, for the purpose of evaluating toxicity and drug efficacy using tissue and applying it to transplantation materials for retinal tissue transplantation treatment It is.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
即ち、本発明は:
[1](1)多能性幹細胞を無血清培地中で浮遊培養することにより多能性幹細胞の凝集体を形成させる第一工程、及び
(2)工程(1)で形成された凝集体を、ソニック・ヘッジホッグシグナル伝達経路作用物質を含まずBMPシグナル伝達経路作用物質を含む無血清培地又は血清培地中で浮遊培養し、網膜前駆細胞を含む凝集体を得る第二工程
を含む、網膜前駆細胞の製造方法(以下、本発明製造方法1と記すこともある。);
[2](1)多能性幹細胞を無血清培地中で浮遊培養することにより多能性幹細胞の凝集体を形成させる第一工程、
(2)工程(1)で形成された凝集体を、ソニック・ヘッジホッグシグナル伝達経路作用物質を含まずBMPシグナル伝達経路作用物質を含む無血清培地又は血清培地中で浮遊培養し、網膜前駆細胞を含む凝集体を得る第二工程、及び
(3)工程(2)で得られた凝集体を、ソニック・ヘッジホッグシグナル伝達経路作用物質、BMPシグナル伝達経路作用物質及びWntシグナル経路作用物質のいずれをも含まない無血清培地又は血清培地中で浮遊培養し、網膜組織を含み頭部非神経外胚葉を実質的に含まない凝集体を得る第三工程
を含む網膜組織の製造方法(以下、本発明製造方法2と記すこともある。);
[3](1)多能性幹細胞を無血清培地中で浮遊培養することにより多能性幹細胞の凝集体を形成させる第一工程、
(2)工程(1)で形成された凝集体を、ソニック・ヘッジホッグシグナル伝達経路作用物質を含まずBMPシグナル伝達経路作用物質を含む無血清培地又は血清培地中で浮遊培養し、網膜前駆細胞を含む凝集体を得る第二工程、及び
(3)工程(2)で得られた凝集体を、ソニック・ヘッジホッグシグナル伝達経路作用物質、BMPシグナル伝達経路作用物質及びWntシグナル経路作用物質のいずれをも含まない無血清培地又は血清培地中で、目的とする網膜層特異的神経細胞が出現するまで浮遊培養し、目的とする網膜層特異的神経細胞を含有する網膜組織を含み頭部非神経外胚葉を実質的に含まない凝集体を得る第三工程
を含む網膜層特異的神経細胞の製造方法(以下、本発明製造方法3と記すこともある。);
[4]前記多能性幹細胞が霊長類多能性幹細胞である前記[1]から[3]のいずれかに記載の製造方法;
[5]前記多能性幹細胞がヒト多能性幹細胞である前記[1]から[4]のいずれかに記載の製造方法;
[6]前記工程(1)及び工程(2)が、血清代替物存在下で行われる前記[1]から[5]のいずれかに記載の製造方法;
[7]浮遊培養が、基底膜標品非存在下で行われる前記[1]から[6]のいずれかに記載の製造方法;
[8]前記BMPシグナル伝達経路作用物質が、BMP2、BMP4、BMP7及びGDF7からなる群から選ばれる1以上の蛋白質である前記[1]から[7]のいずれかに記載の製造方法;
[9]前記BMPシグナル伝達経路作用物質が、工程(1)の浮遊培養開始から1日目から15日目までの間に培地に添加される前記[1]から[8]のいずれかに記載の製造方法;
[10]前記[1]から[9]のいずれかに記載の方法により製造される網膜前駆細胞、網膜組織または網膜層特異的神経細胞を含有してなる、毒性・薬効評価用試薬;
[11]前記[1]から[9]のいずれかに記載の方法により製造される網膜前駆細胞、網膜組織または網膜層特異的神経細胞に被検物質を接触させ、該物質が該細胞又は該組織に及ぼす影響を検定することを含む、該物質の毒性・薬効評価方法;
[12]前記[1]から[9]のいずれかに記載の方法により製造される網膜前駆細胞、網膜組織または網膜層特異的神経細胞を含有してなる、網膜組織の障害に基づく疾患の治療剤;
[13]前記[1]から[9]のいずれかに記載の方法により製造される、有効量の網膜前駆細胞、網膜組織または網膜層特異的神経細胞を、移植を必要とする対象に移植することを含む、網膜組織の障害に基づく疾患の治療方法;及び
[14]網膜組織の障害に基づく疾患の治療における使用のための前記[1]から[9]のいずれかに記載の方法により製造される網膜前駆細胞、網膜組織または網膜層特異的神経細胞;
等を提供する。
このようなベクターのうち、クローニングに適したベクターを「クローニングベクター」と記すこともある。クローニングベクターとしては、通常、制限酵素部位を複数含むマルチプルクローニング部位を含むベクターを挙げることができ、例えば、「Molecular Cloning(3rd edition)」 by Sambrook, J and Russell, D.W., Appendix 3 (Volume 3), Vectors and Bacterial strains. A3.2 (Cold Spring Harbor USA, 2001))に記載されたベクターを挙げることができる。
浮遊培養を行う際に用いられる培養器は、「浮遊培養する」ことが可能なものであれば特に限定されず、当業者であれば適宜決定することが可能である。このような培養器としては、例えば、フラスコ、組織培養用フラスコ、ディッシュ、ペトリデッシュ、組織培養用ディッシュ、マルチディッシュ、マイクロプレート、マイクロウェルプレート、マイクロポア、マルチプレート、マルチウェルプレート、チャンバースライド、シャーレ、チューブ、トレイ、培養バック、又はローラーボトルが挙げられる。これらの培養器は、浮遊培養を可能とするために、細胞非接着性であることが好ましい。細胞非接着性の培養器としては、培養器の表面が、細胞との接着性を向上させる目的で人工的に処理(例えば、細胞外マトリクス等によるコーティング処理)されていないものなどを使用できる。
MatrigelTMは、Engelbreth Holm Swarm(EHS)マウス肉腫から抽出された基底膜調製物である。MatrigelTMの主成分はIV型コラーゲン、ラミニン、ヘパラン硫酸プロテオグリカン及びエンタクチンであり、これらに加えてTGF-β、線維芽細胞増殖因子(FGF)、組織プラスミノゲン活性化因子及びEHS腫瘍が天然に産生する増殖因子が含まれる。MatrigelTMの「growth factor reduced製品」は、通常のMatrigelTMよりも増殖因子の濃度が低く、その標準的な濃度はEGFが<0.5ng/ml、NGFが<0.2ng/ml、PDGFが<5pg/ml、IGF-1が5ng/ml、TGF-βが1.7ng/mlである。
例えば、「BMPシグナル伝達経路作用物質を含む培地」とは、外因性のBMPシグナル伝達経路作用物質が添加された培地または外因性のBMPシグナル伝達経路作用物質を含む培地である。「ソニック・ヘッジホッグシグナル伝達経路作用物質を含まない培地」とは、外因性のソニック・ヘッジホッグシグナル伝達経路作用物質が添加されていない培地または外因性のソニック・ヘッジホッグシグナル伝達経路作用物質を含まない培地である。
幹細胞は、所定の機関より入手でき、また、市販品を購入することもできる。例えば、ヒト胚性幹細胞であるKhES-1、KhES-2及びKhES-3は、京都大学再生医科学研究所より入手可能である。いずれもマウス胚性幹細胞である、EB5細胞は独立行政法人理化学研究所より、D3株はATCCより、入手可能である。
幹細胞は、自体公知の方法により維持培養できる。例えば、ヒト幹細胞は、KnockoutTM Serum Replacement(Invitrogen社)を添加した培地で培養することにより維持できる。マウス幹細胞は、ウシ胎児血清(FCS)及びLeukemiaInhibitory Factor(LIF)を添加し無フィーダー下に培養することにより維持できる。
選別した細胞株の中から目的とする相同組換え体を選択する方法としては、ゲノムDNAに対するサザンハイブリダイゼーション法やPCR法等があげられる。
「凝集体を形成させる」とは、細胞を集合させて細胞の凝集体を形成させ浮遊培養する際に、「一定数の分散した細胞を迅速に凝集」させることで質的に均一な細胞の凝集体を形成させることをいう。
本発明においては、多能性幹細胞を迅速に集合させて多能性幹細胞の凝集体を形成させることが好ましい。このように多能性幹細胞の凝集体を形成させると、形成された凝集体から分化誘導される細胞において上皮様構造を再現性よく形成させることができる。
凝集体を形成させる実験的な操作としては、例えば、ウェルの小さなプレート(96穴プレート)やマイクロポアなどを用いて小さいスペースに細胞を閉じ込める方法、小さな遠心チューブを用いて短時間遠心することで細胞を凝集させる方法が挙げられる。
多能性幹細胞の凝集体が形成されたことや、凝集体を形成する各細胞において上皮様構造が形成されたことは、凝集体のサイズおよび細胞数、巨視的形態、組織染色解析による微視的形態およびその均一性、分化および未分化マーカーの発現およびその均一性、分化マーカーの発現制御およびその同期性、分化効率の凝集体間の再現性などに基づき判断することが可能である。
視細胞前駆細胞、水平細胞前駆細胞、双極細胞前駆細胞、アマクリン細胞前駆細胞、網膜節細胞前駆細胞、網膜色素上皮前駆細胞とは、それぞれ、視細胞、水平細胞、双極細胞、アマクリン細胞、網膜節細胞、網膜色素上皮細胞への分化が決定付けられている前駆細胞をいう。
(1)多能性幹細胞を無血清培地中で浮遊培養することにより多能性幹細胞の凝集体を形成させる第一工程、及び
(2)工程(1)で形成された凝集体を、ソニック・ヘッジホッグシグナル伝達経路作用物質を含まずBMPシグナル伝達経路作用物質を含む無血清培地又は血清培地中で浮遊培養し、網膜前駆細胞を含む凝集体を得る第二工程。
工程(1)における培養温度、CO2濃度等の培養条件は適宜設定できる。培養温度は、例えば約30℃から約40℃、好ましくは約37℃である。CO2濃度は、例えば約1%から約10%、好ましくは約5%である。
多能性幹細胞の凝集体が形成されたことは、凝集体のサイズおよび細胞数、巨視的形態、組織染色解析による微視的形態およびその均一性、分化および未分化マーカーの発現およびその均一性、分化マーカーの発現制御およびその同期性、分化効率の凝集体間の再現性などに基づき判断することが可能である。
かかる培地に用いられる無血清培地又は血清培地は、上述したようなものである限り特に限定されない。調製の煩雑さを回避するには、例えば、市販のKSR等の血清代替物を適量添加した無血清培地(例えば、IMDMとF-12の1:1の混合液に10%KSR、450μM1-モノチオグリセロール及び1xChemically Defined Lipid Concentrateが添加された培地)を使用することが好ましい。無血清培地へのKSRの添加量としては、例えばヒトES細胞の場合は、通常約1%から約20%であり、好ましくは約2%から約20%である。
工程(2)で用いられる無血清培地は、工程(1)で用いた無血清培地がソニック・ヘッジホッグシグナル伝達経路作用物質を含まない限り、当該培地をそのまま用いることもできるし、新たな無血清培地に置き換えることもできる。工程(1)で用いた、BMPシグナル伝達経路物質を含まない無血清培地をそのまま工程(2)に用いる場合、BMPシグナル伝達経路作用物質を培地中に添加すればよい。
「ソニック・ヘッジホッグシグナル伝達経路作用物質を含まない」培地には、ソニック・ヘッジホッグシグナル伝達経路作用物質を実質的に含まない培地、例えば、網膜前駆細胞及び網膜組織への選択的分化に不利な影響を与える程度の濃度のソニック・ヘッジホッグシグナル伝達経路作用物質を含有しない培地、も含まれる。
「ソニック・ヘッジホッグシグナル伝達経路作用物質が添加されていない」培地には、ソニック・ヘッジホッグシグナル伝達経路作用物質が実質的に添加されていない培地、例えば、網膜前駆細胞及び網膜組織への選択的分化に不利な影響を与える程度の濃度のソニック・ヘッジホッグシグナル伝達経路作用物質が添加されていない培地、も含まれる。
BMPシグナル伝達経路作用物質の濃度は、多能性幹細胞の凝集体を形成する細胞の網膜細胞への分化を誘導可能な濃度であればよい。例えばBMP4の場合は、約0.01nMから約1μM、好ましくは約0.1nMから約100nM、より好ましくは約1.5nMの濃度となるように培地に添加する。
BMPシグナル伝達経路作用物質が培地に添加され、多能性幹細胞の凝集体を形成する細胞の網膜細胞への分化誘導が開始された後は、BMPシグナル伝達経路作用物質を培地に添加する必要は無く、BMPシグナル伝達経路作用物質を含まない無血清培地又は血清培地を用いて培地交換を行ってよい。これにより、培地に掛かる経費を抑えることができる。網膜細胞への分化誘導が開始された細胞は、例えば、当該細胞におけるRax遺伝子の発現を検出することにより確認することができる。GFP等の蛍光レポータータンパク質遺伝子がRax遺伝子座へノックインされた多能性幹細胞を用いて工程(1)により形成された凝集体を、網膜細胞への分化誘導に必要な濃度のBMPシグナル伝達経路作用物質の存在下に浮遊培養し、発現した蛍光レポータータンパク質から発せられる蛍光を検出することにより、網膜細胞への分化誘導が開始された時期を確認することもできる。工程(2)の実施態様の一つとして、工程(1)で形成された凝集体を、Rax遺伝子を発現する細胞が出現し始めるまでの間、網膜細胞への分化誘導に必要な濃度のBMPシグナル伝達経路作用物質を含みソニック・ヘッジホッグシグナル伝達経路作用物質を含まない無血清培地又は血清培地中で浮遊培養し、網膜前駆細胞を含む凝集体を得る工程、を挙げることができる。
得られた網膜前駆細胞を含む凝集体は、そのまま毒性・薬効評価用試薬として用いてもよい。網膜前駆細胞を含む凝集体を分散処理(例えば、トリプシン/EDTA処理)し、得られた細胞をFACSを用いて選別することにより、高純度な網膜前駆細胞を得ることも可能である。
(1)多能性幹細胞を無血清培地中で浮遊培養することにより多能性幹細胞の凝集体を形成させる第一工程、
(2)工程(1)で形成された凝集体を、ソニック・ヘッジホッグシグナル伝達経路作用物質を含まずBMPシグナル伝達経路作用物質を含む無血清培地又は血清培地中で浮遊培養し、網膜前駆細胞を含む凝集体を得る第二工程、及び
(3)工程(2)で得られた凝集体を、ソニック・ヘッジホッグシグナル伝達経路作用物質、BMPシグナル伝達経路作用物質及びWntシグナル経路作用物質のいずれをも含まない無血清培地又は血清培地中で浮遊培養し、網膜組織を含み頭部非神経外胚葉を実質的に含まない凝集体を得る第三工程。
「ソニック・ヘッジホッグシグナル伝達経路作用物質、BMPシグナル伝達経路作用物質及びWntシグナル経路作用物質のいずれをも含まない」培地には、ソニック・ヘッジホッグシグナル伝達経路作用物質、BMPシグナル伝達経路作用物質及びWntシグナル経路作用物質のいずれをも実質的に含まない培地、例えば、網膜組織への選択的分化に不利な影響を与える程度の濃度のソニック・ヘッジホッグシグナル伝達経路作用物質、BMPシグナル伝達経路作用物質及びWntシグナル経路作用物質を含有しない培地、も含まれる。
「ソニック・ヘッジホッグシグナル伝達経路作用物質、BMPシグナル伝達経路作用物質及びWntシグナル経路作用物質のいずれもが添加されていない」培地には、ソニック・ヘッジホッグシグナル伝達経路作用物質、BMPシグナル伝達経路作用物質及びWntシグナル経路作用物質のいずれもが実質的に添加されていない培地、例えば、網膜組織への選択的分化に不利な影響を与える程度の濃度のソニック・ヘッジホッグシグナル伝達経路作用物質、BMPシグナル伝達経路作用物質及びWntシグナル経路作用物質が添加されていない培地、も含まれる。
かかる培地に用いられる無血清培地又は血清培地は、上述したようなものである限り特に限定されない。調製の煩雑さを回避するには、例えば、市販のKSR等の血清代替物を適量添加した無血清培地(例えば、IMDMとF-12の1:1の混合液に10%KSR、450μM1-モノチオグリセロール及び1xChemically Defined Lipid Concentrateを添加した培地)を使用することが好ましい。無血清培地へのKSRの添加量としては、例えばヒトES細胞の場合は、通常約1%から約20%であり、好ましくは約2%から約20%である。
工程(3)の培養時間は特に限定されないが、通常48時間以上であり、好ましくは7日間以上である。
凝集体の表面に存在する網膜組織をピンセット等を用いて、凝集体から物理的に切り出すことも可能である。この場合、各凝集体の表面には、網膜組織以外の神経組織が形成される場合もあるため、凝集体から切り出した神経組織の一部を切り取り、これを用いて後述の免疫染色法等により確認することにより、その組織が網膜組織であることを確認することが出来る。
網膜組織を含み頭部非神経外胚葉を実質的に含まない凝集体では、例えば、上述の凝集体凍結切片の免疫染色像において、RAX陽性の組織が観察され、その外側にRAX陰性の組織が観察されない。
得られた網膜組織を含み頭部非神経外胚葉を実質的に含まない凝集体は、そのまま毒性・薬効評価用試薬として用いてもよい。網膜組織を含み頭部非神経外胚葉を実質的に含まない凝集体を分散処理(例えば、トリプシン/EDTA処理)し、得られた細胞をFACSを用いて選別することにより、高純度な網膜組織構成細胞を得ることも可能である。
(1)多能性幹細胞を無血清培地中で浮遊培養することにより多能性幹細胞の凝集体を形成させる第一工程、
(2)工程(1)で形成された凝集体を、ソニック・ヘッジホッグシグナル伝達経路作用物質を含まずBMPシグナル伝達経路作用物質を含む無血清培地又は血清培地中で浮遊培養し、網膜前駆細胞を含む凝集体を得る第二工程、及び
(3)工程(2)で得られた凝集体を、ソニック・ヘッジホッグシグナル伝達経路作用物質、BMPシグナル伝達経路作用物質及びWntシグナル経路作用物質のいずれをも含まない無血清培地又は血清培地中で、目的とする網膜層特異的神経細胞が出現するまで浮遊培養し、目的とする網膜層特異的神経細胞を含有する網膜組織を含み頭部非神経外胚葉を実質的に含まない凝集体を得る第三工程。
「ソニック・ヘッジホッグシグナル伝達経路作用物質、BMPシグナル伝達経路作用物質及びWntシグナル経路作用物質のいずれをも含まない」培地には、ソニック・ヘッジホッグシグナル伝達経路作用物質、BMPシグナル伝達経路作用物質及びWntシグナル経路作用物質のいずれをも実質的に含まない培地、例えば、網膜組織及び網膜層特異的神経細胞への選択的分化に不利な影響を与える程度の濃度のソニック・ヘッジホッグシグナル伝達経路作用物質、BMPシグナル伝達経路作用物質及びWntシグナル経路作用物質を含有しない培地、も含まれる。
「ソニック・ヘッジホッグシグナル伝達経路作用物質、BMPシグナル伝達経路作用物質及びWntシグナル経路作用物質のいずれもが添加されていない」培地には、ソニック・ヘッジホッグシグナル伝達経路作用物質、BMPシグナル伝達経路作用物質及びWntシグナル経路作用物質のいずれもが実質的に添加されていない培地、例えば、網膜組織及び網膜層特異的神経細胞への選択的分化に不利な影響を与える程度の濃度のソニック・ヘッジホッグシグナル伝達経路作用物質、BMPシグナル伝達経路作用物質及びWntシグナル経路作用物質が添加されていない培地、も含まれる。
かかる培地に用いられる無血清培地又は血清培地は、上述したようなものである限り特に限定されない。例えば、DMEM-F12培地に10%ウシ胎児血清、N2サプリメント、100μMタウリン、500nM レチノイン酸を添加した血清培地、市販のKSR等の血清代替物を適量添加した無血清培地(例えば、IMDMとF-12の1:1の混合液に10%KSR、450μM1-モノチオグリセロール及び1xChemically Defined Lipid Concentrateを添加した培地)等を挙げることができる。
工程(3)の培養時間は、目的とする網膜層特異的神経細胞によって異なり、例えば約7日間から約200日間である。
網膜層特異的神経細胞を含有する網膜組織を含み頭部非神経外胚葉を実質的に含まない凝集体では、例えば、上述の凝集体凍結切片の免疫染色像において、RAX陽性の組織が観察され、その外側にRAX陰性の組織が観察されない。
得られた網膜層特異的神経細胞を含有する網膜組織を含み頭部非神経外胚葉を実質的に含まない凝集体は、そのまま毒性・薬効評価用試薬として用いてもよい。網膜層特異的神経細胞を含有する網膜組織を含み頭部非神経外胚葉を実質的に含まない凝集体を分散処理(例えば、トリプシン/EDTA処理)し、得られた細胞をFACSを用いて選別することにより、高純度な網膜層特異的神経細胞を得ることも可能である。
網膜組織又は網膜関連細胞の障害に基づく疾患としては、例えば、有機水銀中毒、クロロキン網膜症、網膜色素変性症、加齢黄斑変性症、緑内障、糖尿病性網膜症、新生児網膜症、などが挙げられる。
RAX::GFPノックインヒトES細胞(KhES-1由来;Cell Stem Cell, 2012, 10(6) 771-785)を「Ueno, M. et al. PNAS 2006, 103(25), 9554-9559」 「Watanabe, K. et al. Nat Biotech 2007, 25, 681-686」に記載の方法に準じて培養した。培地にはDMEM/F12 培地(Sigma)に20%KSR(KnockoutTM Serum Replacement;Invitrogen)、0.1mM 2-メルカプトエタノール、2mM L-グルタミン、1x 非必須アミノ酸、5ng/ml bFGFを添加した培地を用いた。培養された前記ES細胞を、TrypLE Express(Invitrogen)を用いて単一分散した後、単一分散されたES細胞を非細胞接着性の96穴培養プレート(スミロン スフェロイド プレート,住友ベークライト社)の1ウェルあたり1.2×104細胞になるように100μlの無血清培地に浮遊させ、37℃、5%CO2で浮遊培養した。その際の無血清培地には、F-12培地とIMDM培地の1:1混合液に10%KSR、450μM 1-モノチオグリセロール、1x Chemically defined lipid concentrate、20μM Y27632を添加した無血清培地を用いた。浮遊培養開始3日目に終濃度1.5nMのヒト組み換えBMP4(R&D)、終濃度100ng/mlのBMP2(R&D)、終濃度100ng/mlのBMP7(R&D)、終濃度100ng/mlのGDF7(R&D)のうちの何れかを添加して浮遊培養した。前記BMPシグナル伝達経路作用物質をいずれも添加していない条件でも同様に培養した。ウェル内の培養液の半量を、BMPシグナル伝達経路作用物質をいずれも添加していない上記培地に3日おきに交換した。浮遊培養開始18日目に蛍光顕微鏡観察を実施した。BMPシグナル伝達経路作用物質を添加していない条件で培養した場合では網膜前駆細胞が誘導されたことを示すGFP発現細胞がほとんど認められなかった(図1A,B)。それと比べて、BMP2(図1C,D)、BMP4(図1E,F)、BMP7(図1G,H)、GDF7(図1I,J)のいずれかを添加して培養した条件ではGFP発現細胞が明らかに増加した。
RAX::GFPノックインヒトES細胞(KhES-1由来;Cell Stem Cell, 2012, 10(6) 771-785)を「Ueno, M. et al. PNAS 2006, 103(25), 9554-9559」 「Watanabe, K. et al. Nat Biotech 2007, 25, 681-686」に記載の方法に準じて培養した。培地にはDMEM/F12 培地(Sigma)に20%KSR(KnockoutTM Serum Replacement;Invitrogen)、0.1mM 2-メルカプトエタノール、2mM L-グルタミン、1x 非必須アミノ酸、5ng/ml bFGFを添加した培地を用いた。培養された前記ES細胞を、TrypLE Express(Invitrogen)を用いて単一分散した後、単一分散されたES細胞を非細胞接着性の96穴培養プレート(スミロン スフェロイド プレート,住友ベークライト社)の1ウェルあたり1.2×104細胞になるように100μlの無血清培地に浮遊させ、37℃、5%CO2で浮遊培養した。その際の無血清培地には、F-12培地とIMDM培地の1:1混合液に10%KSR、450μM 1-モノチオグリセロール、1x Chemically defined lipid concentrate、20μM Y27632を添加した無血清培地を用いた。浮遊培養開始と同時、浮遊培養開始1日目、浮遊培養開始2日目、浮遊培養開始3日目のいずれかの時点で終濃度1.5nMのヒト組み換えBMP4(R&D)を添加して浮遊培養した。BMPシグナル伝達経路作用物質を添加していない条件でも同様に培養した。ウェル内の培養液の半量を、BMPシグナル伝達経路作用物質を添加していない上記培地に3日おきに交換した。浮遊培養開始18日目に96wellプレートから浮遊培養用ディッシュへと凝集体を移し、引き続きF-12培地とIMDM培地の1:1混合液に10%KSR、450μM 1-モノチオグリセロール、1x Chemically defined lipid concentrateを添加した無血清培地中で浮遊培養を行った。浮遊培養開始26日目に蛍光顕微鏡による観察およびFACSによるGFP陽性細胞の割合の測定を行った。
BMPシグナル伝達経路作用物質を添加していない条件(図2A,B,C)および浮遊培養開始と同時にBMP4を添加した条件(図2D,E,F)では網膜前駆細胞が誘導されたことを示すGFP発現細胞は認められなかった。それと比べて、浮遊培養開始1日目(図2G,H,I)、浮遊培養開始2日目(図2J,K,L)、浮遊培養開始3日目(図2M,N,O)のいずれかの時点でBMP4を添加した条件では、GFP発現細胞が明らかに増加した。いずれの条件においても、形成されたRAX::GFP陽性の組織の外側にRAX::GFP陰性の組織は観察されなかった。FACSによる測定の結果では、浮遊培養開始3日目にBMP4を添加した条件では85%以上の細胞がGFP陽性であった(図2O)。以上の結果から、網膜組織を含み頭部非神経外胚葉を実質的に含まない凝集体の製造には、BMPシグナル伝達経路作用物質を浮遊培養開始1日目以降、好ましくは3日目に添加することが有効であることが示された。
RAX::GFPノックインヒトES細胞(KhES-1由来;Cell Stem Cell, 2012, 10(6) 771-785)を「Ueno, M. et al. PNAS 2006, 103(25), 9554-9559」 「Watanabe, K. et al. Nat Biotech 2007, 25, 681-686」に記載の方法に準じて培養した。培地にはDMEM/F12 培地(Sigma)に20%KSR(KnockoutTM Serum Replacement;Invitrogen)、0.1mM 2-メルカプトエタノール、2mM L-グルタミン、1x 非必須アミノ酸、5ng/ml bFGFを添加した培地を用いた。培養された前記ES細胞を、TrypLE Express(Invitrogen)を用いて単一分散した後、単一分散されたES細胞を非細胞接着性の96穴培養プレート(スミロン スフェロイド プレート,住友ベークライト社)の1ウェルあたり1.2×104細胞になるように100μlの無血清培地に浮遊させ、37℃、5%CO2で浮遊培養した。その際の無血清培地には、F-12培地とIMDM培地の1:1混合液に10%KSR、450μM 1-モノチオグリセロール、1x Chemically defined lipid concentrate、20μM Y27632を添加した無血清培地を用いた。浮遊培養開始6日目、浮遊培養開始9日目、浮遊培養開始12日目、浮遊培養開始15日目のいずれかの時点で終濃度1.5nMのヒト組み換えBMP4(R&D)を添加して浮遊培養した。BMPシグナル伝達経路作用物質を添加していない条件でも同様に培養した。ウェル内の培養液の半量を、BMPシグナル伝達経路作用物質を添加していない上記培地に3日おきに交換した。浮遊培養開始18日目に、96wellプレートから浮遊培養用ディッシュへと凝集体を移し、引き続きF-12培地とIMDM培地の1:1混合液に10%KSR、450μM 1-モノチオグリセロール、1x Chemically defined lipid concentrateを添加した無血清培地で浮遊培養を行った。浮遊培養開始24日目に、蛍光顕微鏡観察を実施した。
その結果、BMPシグナル伝達経路作用物質を添加していない条件では網膜前駆細胞が誘導されたことを示すGFP発現細胞は認められなかった(図3A,B)。それと比べて、浮遊培養開始6日目(図3C,D)、浮遊培養開始9日目(図3E,F)、浮遊培養開始12日目(図3G,H)のいずれかの時点でBMP4を添加した条件では明らかにGFP発現細胞が増加した。浮遊培養開始15日目にBMP4を添加した条件でもGFP発現細胞が誘導されたものの、効率は低かった(図3I,J)。いずれの条件においても、形成されたRAX::GFP陽性の組織の外側にRAX::GFP陰性の組織は観察されなかった。以上の結果から、網膜組織を含み頭部非神経外胚葉を実質的に含まない凝集体の製造には、BMPシグナル伝達経路作用物質を浮遊培養開始15日目以前に添加することが有効であることが示された。
実施例1で得られたGFP発現細胞を含む凝集体を、浮遊培養開始18日目に96wellプレートから浮遊培養用ディッシュへと凝集体を移し、引き続きF-12培地とIMDM培地の1:1混合液に10%KSR、450μM 1-モノチオグリセロール、1x Chemically defined lipid concentrateを添加した培地で浮遊培養を実施した。浮遊培養開始26日目に凝集体を4%パラホルムアルデヒド溶液で固定し、凍結切片を作製した後、免疫染色法により組織構造の確認を行った。
浮遊培養開始26日目において、全層がRAX::GFP陽性であり、外層が網膜幹細胞のマーカーであるChx10陽性であった(図4A, B, C)。RAX::GFP陽性の上皮の外側には非神経外胚葉等のいかなる組織も存在しなかった。本発明製造方法により、ヒトES細胞から高効率に網膜組織が製造可能であることが示された。
RAX::GFPノックインヒトES細胞(KhES-1由来;Cell Stem Cell, 2012, 10(6) 771-785)を「Ueno, M. et al. PNAS 2006, 103(25), 9554-9559」 「Watanabe, K. et al. Nat Biotech 2007, 25, 681-686」に記載の方法に準じて培養した。培地にはDMEM/F12 培地(Sigma)に20%KSR(KnockoutTM Serum Replacement;Invitrogen)、0.1mM 2-メルカプトエタノール、2mM L-グルタミン、1x 非必須アミノ酸、5ng/ml bFGFを添加した培地を用いた。培養された前記ES細胞を、TrypLE Express(Invitrogen)を用いて単一分散した後、単一分散されたES細胞を非細胞接着性の96穴培養プレート(スミロン スフェロイド プレート,住友ベークライト社)の1ウェルあたり1.2×104細胞になるように100μlの無血清培地に浮遊させ、37℃、5%CO2で浮遊培養した。その際の無血清培地には、F-12培地とIMDM培地の1:1混合液に10%KSR、450μM 1-モノチオグリセロール、1x Chemically defined lipid concentrate、20μM Y27632を添加した無血清培地を用いた。浮遊培養開始3日目に終濃度1.5nMのヒト組み換えBMP4(R&D)を添加した。ウェル内の培養液の半量を、BMPシグナル伝達経路作用物質を添加していない上記培地に3日おきに交換した。浮遊培養開始18日目に96wellプレートから浮遊培養用ディッシュへと凝集体を移し、DMEM-F12培地に10%ウシ胎児血清、N2サプリメント、100μMタウリン、500nM レチノイン酸を添加した培地を用いて浮遊培養を継続した。浮遊培養開始18日目以降の培養は40%O2下で実施した。浮遊培養開始117日目に凝集体を4%パラホルムアルデヒド溶液で固定し、凍結切片を作製した後、免疫染色法により組織構造の確認を行った。浮遊培養開始117日目において、全層がRAX::GFP陽性であり、視細胞マーカーであるRecoverinが陽性の細胞が存在した(図5A)。くわえて、網膜組織外層に、棹体視細胞マーカーであるNrlが陽性の細胞(図5B)と、錐体視細胞マーカーであるRXR-gammaが陽性の細胞(図5C)が存在し、棹体、錐体視細胞への分化が生じていることが示された。さらに、網膜前駆細胞及び双極細胞のマーカーであるChx10が陽性の細胞(図5D)、アマクリン細胞マーカーであるCalretininが陽性の細胞(図5 E)、水平細胞マーカーであるCalbindinが陽性の細胞(図5F)が存在していた。この結果から、本発明製造方法により、各種の分化した網膜層特異的神経細胞から構成される網膜組織を、ヒトES細胞から高効率に製造可能であることが示された。
RAX::GFPノックインヒトES細胞(KhES-1由来;Cell Stem Cell, 2012, 10(6) 771-785)を、「Ueno, M. et al. PNAS 2006, 103(25), 9554-9559」 「Watanabe, K. et al. Nat Biotech 2007, 25, 681-686」に記載の方法に準じて培養した。培地にはDMEM/F12 培地(Sigma)に20%KSR(KnockoutTM Serum Replacement;Invitrogen)、0.1mM 2-メルカプトエタノール、2mM L-グルタミン、1x 非必須アミノ酸、8ng/ml bFGFを添加した培地を用いた。培養された前記ES細胞を、TrypLE Express(Invitrogen)を用いて単一分散した後、単一分散されたES細胞を非細胞接着性の96穴培養プレート(スミロン スフェロイド プレート,住友ベークライト社)の1ウェルあたり1.2×104細胞になるように100μlの無血清培地に浮遊させ、37℃、5%CO2で浮遊培養した。その際の無血清培地には、F-12培地とIMDM培地の1:1混合液に10%KSR、450μM 1-モノチオグリセロール、1x Chemically defined lipid concentrate、20μM Y27632を添加した無血清培地を用いた。浮遊培養開始3日目に、前記無血清培地を50μl加えた(合計150μl)。浮遊培養開始6日目に終濃度1.5nMのヒト組み換えBMP4(R&D)を添加した。ウェル内の培養液の半量を、BMPシグナル伝達経路作用物質を添加していない上記培地に3日おきに交換した。浮遊培養開始18日目に96wellプレートから浮遊培養用ディッシュへと凝集体を移し、DMEM-F12培地に10%ウシ胎児血清、N2サプリメント、100μMタウリン、500nM レチノイン酸を添加した培地を用いて浮遊培養を継続した。浮遊培養開始18日目以降の培養は40%O2下で実施した。浮遊培養開始50日目に凝集体を4%パラホルムアルデヒド溶液で固定し、凍結切片を作製した後、免疫染色法により組織構造の確認を行った。浮遊培養開始50日目において、全層がRAX::GFP陽性であり、網膜前駆細胞及び双極細胞のマーカーであるChx10が陽性の細胞(図6A)、神経節細胞及び神経細胞のマーカーであるPax6陽性の細胞(図6B)が存在し、多層の網膜神経組織が形成されていることが示された。くわえて、視細胞マーカーであるCrxが陽性の細胞(図6C)、及び、神経節細胞のマーカーであるBrn3b陽性の細胞(図6D)が存在した。この結果から、本発明製造方法により、各種の分化した網膜層特異的神経細胞から構成される網膜組織を、ヒトES細胞から高効率に製造可能であることが示された。
ヒトiPS細胞株201B7(独立行政法人理化学研究所バイオリソースセンター又はiPSアカデミアジャパン株式会社から入手可能)を「Ueno, M. et al. PNAS 2006, 103(25), 9554-9559」 「Watanabe, K. et al. Nat Biotech 2007, 25, 681-686」に記載の方法に準じて培養する。培地にはDMEM/F12 培地(Sigma)に20%KSR(KnockoutTM Serum Replacement;Invitrogen)、0.1mM 2-メルカプトエタノール、2mM L-グルタミン、1x 非必須アミノ酸、5ng/ml bFGFを添加した培地を用いる。培養された前記iPS細胞を、TrypLE Express(Invitrogen)を用いて単一分散した後、非細胞接着性の96穴培養プレート(スミロン スフェロイド プレート,住友ベークライト社)の1ウェルあたり1.2×104細胞になるように100μlの無血清培地に浮遊させ、37℃、5%CO2で浮遊培養する。その際の無血清培地には、F-12培地とIMDM培地の1:1混合液に10%KSR、450μM 1-モノチオグリセロール、1x Chemically defined lipid concentrate、20μM Y27632を添加した無血清培地を用いる。浮遊培養開始1日目から15日目の何れかの時点に、終濃度1.5nMのヒト組み換えBMP4(R&D)、終濃度100ng/mlのBMP2(R&D)、終濃度100ng/mlのBMP7(R&D)、終濃度100ng/mlのGDF7(R&D)のうちの何れかを添加して浮遊培養を行う。ウェル内の培養液の半量を、BMPシグナル伝達経路作用物質をいずれも添加していない上記培地に3日おきに交換する。浮遊培養開始18日目に凝集体を一部回収し、4%パラホルムアルデヒドで固定処理を実施し凍結切片を作製した後、免疫染色法により網膜前駆細胞マーカー(Rax、Chx10)の発現を確認する。残りの凝集体を96wellプレートから浮遊培養用ディッシュへと移し、DMEM-F12培地に10%ウシ胎児血清、N2サプリメント、100μMタウリン、500nM レチノイン酸を添加した培地を用いて浮遊培養を継続する。浮遊培養開始18日目以降の培養は40%O2下で実施する。浮遊培養開始117日目に凝集体を4%パラホルムアルデヒド溶液で固定し、凍結切片を作製した後、免疫染色法により組織構造と網膜層特異的神経細胞のマーカー(Nrl、RXR-gamma、Recoverin、Chx10、Calretinin、Calbindin)の発現の確認を行う。
このようにして、網膜前駆細胞、更には、各種の分化した網膜層特異的神経細胞から構成される網膜組織を、ヒトiPS細胞から製造可能である。
Claims (14)
- (1)多能性幹細胞を無血清培地中で浮遊培養することにより多能性幹細胞の凝集体を形成させる第一工程、及び
(2)工程(1)で形成された凝集体を、ソニック・ヘッジホッグシグナル伝達経路作用物質を含まずBMPシグナル伝達経路作用物質を含む無血清培地又は血清培地中で浮遊培養し、網膜前駆細胞を含む凝集体を得る第二工程
を含む、網膜前駆細胞の製造方法。 - (1)多能性幹細胞を無血清培地中で浮遊培養することにより多能性幹細胞の凝集体を形成させる第一工程、
(2)工程(1)で形成された凝集体を、ソニック・ヘッジホッグシグナル伝達経路作用物質を含まずBMPシグナル伝達経路作用物質を含む無血清培地又は血清培地中で浮遊培養し、網膜前駆細胞を含む凝集体を得る第二工程、及び
(3)工程(2)で得られた凝集体を、ソニック・ヘッジホッグシグナル伝達経路作用物質、BMPシグナル伝達経路作用物質及びWntシグナル経路作用物質のいずれをも含まない無血清培地又は血清培地中で浮遊培養し、網膜組織を含み頭部非神経外胚葉を実質的に含まない凝集体を得る第三工程
を含む網膜組織の製造方法。 - (1)多能性幹細胞を無血清培地中で浮遊培養することにより多能性幹細胞の凝集体を形成させる第一工程、
(2)工程(1)で形成された凝集体を、ソニック・ヘッジホッグシグナル伝達経路作用物質を含まずBMPシグナル伝達経路作用物質を含む無血清培地又は血清培地中で浮遊培養し、網膜前駆細胞を含む凝集体を得る第二工程、及び
(3)工程(2)で得られた凝集体を、ソニック・ヘッジホッグシグナル伝達経路作用物質、BMPシグナル伝達経路作用物質及びWntシグナル経路作用物質のいずれをも含まない無血清培地又は血清培地中で、目的とする網膜層特異的神経細胞が出現するまで浮遊培養し、目的とする網膜層特異的神経細胞を含有する網膜組織を含み頭部非神経外胚葉を実質的に含まない凝集体を得る第三工程
を含む網膜層特異的神経細胞の製造方法。 - 前記多能性幹細胞が霊長類多能性幹細胞である請求項1から3のいずれか1項に記載の製造方法。
- 前記多能性幹細胞がヒト多能性幹細胞である請求項1から4のいずれか1項に記載の製造方法。
- 前記工程(1)及び工程(2)が、血清代替物存在下で行われる請求項1から5のいずれか1項に記載の製造方法。
- 浮遊培養が、基底膜標品非存在下で行われる請求項1から6のいずれか1項に記載の製造方法。
- 前記BMPシグナル伝達経路作用物質が、BMP2、BMP4、BMP7及びGDF7からなる群から選ばれる1以上の蛋白質である請求項1から7のいずれか1項に記載の製造方法。
- 前記BMPシグナル伝達経路作用物質が、工程(1)の浮遊培養開始から1日目から15日目までの間に培地に添加される請求項1から8のいずれか1項に記載の製造方法。
- 請求項1から9のいずれか1項に記載の方法により製造される網膜前駆細胞、網膜組織または網膜層特異的神経細胞を含有してなる、毒性・薬効評価用試薬。
- 請求項1から9のいずれか1項に記載の方法により製造される網膜前駆細胞、網膜組織または網膜層特異的神経細胞に被検物質を接触させ、該物質が該細胞又は該組織に及ぼす影響を検定することを含む、該物質の毒性・薬効評価方法。
- 請求項1から9のいずれか1項に記載の方法により製造される網膜前駆細胞、網膜組織または網膜層特異的神経細胞を含有してなる、網膜組織の障害に基づく疾患の治療剤。
- 請求項1から9のいずれか1項に記載の方法により製造される、有効量の網膜前駆細胞、網膜組織または網膜層特異的神経細胞を、移植を必要とする対象に移植することを含む、網膜組織の障害に基づく疾患の治療方法。
- 網膜組織の障害に基づく疾患の治療における使用のための請求項1から9のいずれか1項に記載の方法により製造される網膜前駆細胞、網膜組織または網膜層特異的神経細胞。
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015532926A JP6580989B2 (ja) | 2013-08-23 | 2014-08-22 | 網膜組織及び網膜関連細胞の製造方法 |
KR1020167007728A KR102278978B1 (ko) | 2013-08-23 | 2014-08-22 | 망막 조직 및 망막 관련 세포의 제조 방법 |
EP14838289.8A EP3037524B8 (en) | 2013-08-23 | 2014-08-22 | Method for producing retinal tissue and retina-related cells |
SG11201601294PA SG11201601294PA (en) | 2013-08-23 | 2014-08-22 | Method for producing retinal tissue and retina-related cells |
US14/913,628 US10501724B2 (en) | 2013-08-23 | 2014-08-22 | Method for producing retinal tissue and retina-related cells |
AU2014309730A AU2014309730B2 (en) | 2013-08-23 | 2014-08-22 | Method for producing retinal tissue and retina-related cells |
CN201480056996.6A CN105683366B (zh) | 2013-08-23 | 2014-08-22 | 用于制备视网膜组织和视网膜相关细胞的方法 |
ES14838289T ES2776707T3 (es) | 2013-08-23 | 2014-08-22 | Método para producir tejido retiniano y células relacionadas con la retina |
EP19212683.7A EP3656853B1 (en) | 2013-08-23 | 2014-08-22 | Method for producing retinal tissue and retina-related cells |
DK14838289.8T DK3037524T3 (da) | 2013-08-23 | 2014-08-22 | Fremgangsmåde til at fremstille nethindevæv og nethinderelaterede celler |
CA2922079A CA2922079C (en) | 2013-08-23 | 2014-08-22 | Method for producing retinal tissue and retina-related cells |
US16/692,484 US11473056B2 (en) | 2013-08-23 | 2019-11-22 | Method for producing retinal tissue and retina-related cells |
US17/870,569 US20220364054A1 (en) | 2013-08-23 | 2022-07-21 | Method for producing retinal tissue and retina-related cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013173285 | 2013-08-23 | ||
JP2013-173285 | 2013-08-23 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/913,628 A-371-Of-International US10501724B2 (en) | 2013-08-23 | 2014-08-22 | Method for producing retinal tissue and retina-related cells |
US16/692,484 Continuation US11473056B2 (en) | 2013-08-23 | 2019-11-22 | Method for producing retinal tissue and retina-related cells |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015025967A1 true WO2015025967A1 (ja) | 2015-02-26 |
Family
ID=52483737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/072065 WO2015025967A1 (ja) | 2013-08-23 | 2014-08-22 | 網膜組織及び網膜関連細胞の製造方法 |
Country Status (11)
Country | Link |
---|---|
US (3) | US10501724B2 (ja) |
EP (2) | EP3656853B1 (ja) |
JP (4) | JP6580989B2 (ja) |
KR (1) | KR102278978B1 (ja) |
CN (1) | CN105683366B (ja) |
AU (1) | AU2014309730B2 (ja) |
CA (1) | CA2922079C (ja) |
DK (1) | DK3037524T3 (ja) |
ES (2) | ES2943670T3 (ja) |
SG (1) | SG11201601294PA (ja) |
WO (1) | WO2015025967A1 (ja) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017043604A1 (ja) * | 2015-09-08 | 2017-03-16 | 大日本住友製薬株式会社 | 網膜組織の製造方法 |
WO2017090741A1 (ja) * | 2015-11-25 | 2017-06-01 | 国立研究開発法人理化学研究所 | 細胞塊に関する領域検出方法及び領域検出装置 |
WO2018097253A1 (ja) | 2016-11-25 | 2018-05-31 | 国立研究開発法人理化学研究所 | 移植用細胞集団及びその製造方法 |
WO2019017491A1 (ja) | 2017-07-20 | 2019-01-24 | 国立研究開発法人理化学研究所 | 神経組織の保存方法 |
WO2019017492A1 (ja) | 2017-07-20 | 2019-01-24 | 国立研究開発法人理化学研究所 | 連続的な上皮を含む網膜組織の成熟化方法 |
WO2019050015A1 (ja) | 2017-09-08 | 2019-03-14 | 国立研究開発法人理化学研究所 | 網膜組織を含む細胞凝集体及びその製造方法 |
WO2019054515A1 (ja) | 2017-09-14 | 2019-03-21 | 国立研究開発法人理化学研究所 | 背側化シグナル伝達物質又は腹側化シグナル伝達物質による錐体視細胞又は桿体視細胞の増加方法 |
WO2019054514A1 (ja) | 2017-09-14 | 2019-03-21 | 国立研究開発法人理化学研究所 | 網膜組織の製造方法 |
WO2020138430A1 (ja) | 2018-12-28 | 2020-07-02 | 国立研究開発法人理化学研究所 | 網膜系細胞又は網膜組織の障害を伴う疾患の治療薬 |
US10760050B2 (en) | 2013-11-11 | 2020-09-01 | Sumitomo Chemical Company, Limited | Method for producing retinal pigment epithelial cells |
WO2020184720A1 (ja) | 2019-03-13 | 2020-09-17 | 大日本住友製薬株式会社 | 移植用神経網膜の品質を評価する方法及び移植用神経網膜シート |
WO2020218480A1 (ja) | 2019-04-26 | 2020-10-29 | 国立研究開発法人理化学研究所 | 神経網膜と網膜色素上皮細胞とハイドロゲルとを含む複合体及びその製造方法 |
US11214771B2 (en) | 2014-10-24 | 2022-01-04 | Sumitomo Dainippon Pharma Co., Ltd. | Production method for nerve tissue |
US11214772B2 (en) | 2014-10-24 | 2022-01-04 | Sumitomo Dainippon Pharma Co., Ltd. | Production method for retinal tissue |
US11241460B2 (en) | 2013-03-15 | 2022-02-08 | Astellas Institute For Regenerative Medicine | Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells |
WO2022054924A1 (ja) | 2020-09-11 | 2022-03-17 | 大日本住友製薬株式会社 | 移植用組織のための媒体 |
WO2022054925A1 (ja) | 2020-09-11 | 2022-03-17 | 国立研究開発法人理化学研究所 | 神経網膜を含む細胞凝集体とマトリクスとを含む複合体及びその製造方法 |
US11371016B2 (en) | 2016-04-22 | 2022-06-28 | Sumitomo Pharma Co., Ltd. | Method for producing retinal tissue |
WO2023090427A1 (ja) | 2021-11-19 | 2023-05-25 | 国立研究開発法人理化学研究所 | シート状網膜組織の製造方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2014CN04599A (ja) * | 2011-11-25 | 2015-09-18 | Sumitomo Chemical Co | |
WO2017160147A1 (en) * | 2016-03-15 | 2017-09-21 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Organotypic culture system |
SG11202004831QA (en) * | 2017-11-24 | 2020-06-29 | Sumitomo Chemical Co | Production method for cell mass including neural cells/tissue and non-neural epithelial tissue, and cell mass from same |
GB2584664B (en) * | 2019-06-10 | 2023-05-24 | Newcells Biotech Ltd | Improved retinal organoids and methods of making the same |
CN116445409B (zh) * | 2023-06-16 | 2023-09-22 | 中国人民解放军总医院第三医学中心 | 视杆感光前体细胞的制备方法及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998030679A1 (en) | 1997-01-10 | 1998-07-16 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
WO2006053629A1 (de) * | 2004-11-16 | 2006-05-26 | Universitätsklinikum Hamburg-Eppendorf | In vitro aus knochenmarkstammzellen differenzierte retina-spezifische zellen, ihre herstelllung und verwendung |
WO2011055855A1 (en) | 2009-11-05 | 2011-05-12 | Riken | A method for differentiation induction in cultured stem cells |
WO2013077425A1 (ja) | 2011-11-25 | 2013-05-30 | 住友化学株式会社 | 網膜組織及び網膜関連細胞の製造方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4458222B2 (ja) | 2000-05-16 | 2010-04-28 | 独立行政法人理化学研究所 | 胚性幹細胞の外胚葉系細胞への新規な分化誘導法及びその用途 |
US20060281179A1 (en) | 2001-11-15 | 2006-12-14 | Yoshiki Sasai | Inducer for differentiation of embryo stem cells into ectodermal cells method of obtaining the same and use thereof |
US8492147B2 (en) | 2004-06-18 | 2013-07-23 | Riken | Method of inducing the differentiation of embryonic stem cells into nerve by serum-free suspension culture |
CN1973541A (zh) * | 2004-06-21 | 2007-05-30 | 皇家飞利浦电子股份有限公司 | 使用扫描速率变换的图像处理器和图像处理方法 |
CA2574777C (en) | 2004-07-23 | 2015-09-01 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
EP2128244A4 (en) * | 2007-01-18 | 2012-05-09 | Riken | INDUCTION / DIFFERENTIATION METHOD IN PHOTORECEPTOR CELL |
TW202021980A (zh) * | 2007-02-02 | 2020-06-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
EP2554661B2 (en) * | 2007-04-18 | 2018-02-21 | Hadasit Medical Research Services & Development Limited | Stem cell-derived retinal pigment epithelial cells |
CN104946591A (zh) | 2007-10-12 | 2015-09-30 | 奥卡塔治疗公司 | 制备rpe 细胞和rpe 细胞的组合物的改良方法 |
CA2721952C (en) | 2008-04-22 | 2019-11-12 | Regenerative Research Foundation | Retinal pigment epithelial stem cells |
JP6166900B2 (ja) | 2009-08-24 | 2017-07-19 | ウイスコンシン アラムナイ リサーチ ファウンデーシヨンWisconsin Alumni Research Foundation | 実質的に純粋なヒト網膜前駆細胞培養物、前脳前駆細胞培養物、網膜色素上皮細胞培養物、及び、それらの製造方法 |
CN102712900B (zh) * | 2009-10-06 | 2015-07-01 | 首尔大学校产学协力团 | 干细胞分化成为视网膜细胞的方法 |
AU2010365057B2 (en) | 2010-12-08 | 2016-12-22 | Viacyte, Inc. | Agents and methods for inhibiting human pluripotent stem cell growth |
EP3530730B1 (en) | 2011-10-31 | 2022-07-20 | Riken | Method for culturing stem cell |
JP2013173285A (ja) | 2012-02-27 | 2013-09-05 | Casio Electronics Co Ltd | 印刷装置 |
JP6546089B2 (ja) | 2013-08-06 | 2019-07-17 | 国立研究開発法人理化学研究所 | 前眼部組織の製造方法 |
-
2014
- 2014-08-22 EP EP19212683.7A patent/EP3656853B1/en active Active
- 2014-08-22 KR KR1020167007728A patent/KR102278978B1/ko active IP Right Grant
- 2014-08-22 AU AU2014309730A patent/AU2014309730B2/en active Active
- 2014-08-22 CN CN201480056996.6A patent/CN105683366B/zh active Active
- 2014-08-22 JP JP2015532926A patent/JP6580989B2/ja active Active
- 2014-08-22 ES ES19212683T patent/ES2943670T3/es active Active
- 2014-08-22 ES ES14838289T patent/ES2776707T3/es active Active
- 2014-08-22 SG SG11201601294PA patent/SG11201601294PA/en unknown
- 2014-08-22 WO PCT/JP2014/072065 patent/WO2015025967A1/ja active Application Filing
- 2014-08-22 CA CA2922079A patent/CA2922079C/en active Active
- 2014-08-22 EP EP14838289.8A patent/EP3037524B8/en active Active
- 2014-08-22 DK DK14838289.8T patent/DK3037524T3/da active
- 2014-08-22 US US14/913,628 patent/US10501724B2/en active Active
-
2019
- 2019-08-29 JP JP2019156823A patent/JP6885550B2/ja active Active
- 2019-11-22 US US16/692,484 patent/US11473056B2/en active Active
-
2021
- 2021-04-28 JP JP2021076107A patent/JP7120585B2/ja active Active
-
2022
- 2022-07-21 US US17/870,569 patent/US20220364054A1/en active Pending
- 2022-07-27 JP JP2022119438A patent/JP7435984B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998030679A1 (en) | 1997-01-10 | 1998-07-16 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
WO2006053629A1 (de) * | 2004-11-16 | 2006-05-26 | Universitätsklinikum Hamburg-Eppendorf | In vitro aus knochenmarkstammzellen differenzierte retina-spezifische zellen, ihre herstelllung und verwendung |
WO2011055855A1 (en) | 2009-11-05 | 2011-05-12 | Riken | A method for differentiation induction in cultured stem cells |
WO2013077425A1 (ja) | 2011-11-25 | 2013-05-30 | 住友化学株式会社 | 網膜組織及び網膜関連細胞の製造方法 |
Non-Patent Citations (31)
Title |
---|
"Bio Manual series 8, gene targeting, Production of mutant mouse by using ES cells", 1995, YODOSHA CO., LTD. |
"Current Protocols in Molecular Biology", 1987, JOHN WILEY & SONS |
"Gene Targeting, A Practical Approach", 1993, IRL PRESS AT OXFORD UNIVERSITY PRESS |
"Manipulating the Mouse Embryo, A Laboratory Manual", 1994, COLD SPRING HARBOR LABORATORY PRESS |
"Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
"transgene & expression analysis experiment method", 1997, YODOSHA CO., LTD. |
AUSUBEL F. A. ET AL.: "Current Protocols in Molecular Biology", 1988, WILEY |
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 199, 1994, pages 552 |
CELL STEM CELL, vol. 10, no. 6, 2012, pages 771 - 785 |
CELL, vol. 126, no. 4, 2006, pages 663 - 676 |
CELL, vol. 131, no. 5, 2007, pages 861 - 872 |
DEV. BIOL., vol. 168, 1995, pages 342 |
FURUTA Y. ET AL.: "BMP4 is essential for lens induction in the mouse embryo", GENES DEV., vol. 12, no. 23, 1998, pages 3764 - 3775, XP055006571 * |
GENES&DEVELOPMENT, vol. 15, 2003, pages 3023 - 3028 |
HANAKO IKEDA ET AL.: "Kansaibo no Kisoteki Kenkyu Dai 2 Sho Kansaibo no Unmei o Kaeru Shikumi 2. ES Saibo o Mochiita Shikenkan-nai deno Shinkei Bunka Yudo - Shuno Zenku Saibo to Shinkei Momaku Zenku Saibo", EXPERIMENTAL MEDICINE, vol. 24, no. 2, 2006, pages 188 - 194, XP008182863 * |
J. NEUROSCI., vol. 16, 1996, pages 1056 |
LAMBA D.A. ET AL.: "Efficient generation of retinal progenitor cells from human embryonic stem cells", PNAS, vol. 103, no. 34, 2006, pages 12769 - 12774, XP008155440 * |
LANG R.A. ET AL.: "Pathways regulating lens induction in the mouse", INT. J. DEV. BIOL., vol. 48, 2004, pages 783 - 791, XP055321537 * |
NAT. BIOTECHNOL., vol. 26, no. 1, 2008, pages 101 - 106 |
NATURE, vol. 376, 1995, pages 333 - 336 |
NATURE, vol. 472, 2011, pages 51 - 56 |
OSAKADA F. ET AL.: "Control of neural differentiation from pluripotent stem cells", INFLAMM REGEN, vol. 28, no. 3, 2008, pages 166 - 173, XP055321518 * |
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1987, COLD SPRING HARBOR LABORATORY PRESS, COLD SPRING HARBOR |
SAMBROOK J. ET AL.: "Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS, COLD SPRING HARBOR |
SAMBROOK, J; RUSSELL, D.W.: "Vectors and Bacterial strains", vol. 3, 2001, COLD SPRING HARBOR, article "Molecular Cloning" |
SCIENCE, vol. 318, no. 5858, 2007, pages 1917 - 1920 |
TROUSSE F. ET AL.: "Bmp4 mediates apoptotic cell death in the developing chick eye", J NEUROSCI., vol. 21, no. 4, 2001, pages 1292 - 1301, XP055321540 * |
UENO, M. ET AL., PNAS, vol. 103, no. 25, 2006, pages 9554 - 9559 |
WATANABE K. ET AL.: "Directed differentiation of telencephalic precursors from embryonic stem cells", NATURE NEUROSCIENCE, vol. 8, no. 3, 2005, pages 288 - 296, XP002487263 * |
WATANABE, K. ET AL., NAT BIOTECH, vol. 25, 2007, pages 681 - 686 |
YAMANAKA ET AL., MOUSE CELL, 2006 |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11241460B2 (en) | 2013-03-15 | 2022-02-08 | Astellas Institute For Regenerative Medicine | Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells |
US10760050B2 (en) | 2013-11-11 | 2020-09-01 | Sumitomo Chemical Company, Limited | Method for producing retinal pigment epithelial cells |
US11214771B2 (en) | 2014-10-24 | 2022-01-04 | Sumitomo Dainippon Pharma Co., Ltd. | Production method for nerve tissue |
US11214772B2 (en) | 2014-10-24 | 2022-01-04 | Sumitomo Dainippon Pharma Co., Ltd. | Production method for retinal tissue |
JP7154546B2 (ja) | 2015-09-08 | 2022-10-18 | 住友ファーマ株式会社 | 網膜組織の製造方法 |
WO2017043604A1 (ja) * | 2015-09-08 | 2017-03-16 | 大日本住友製薬株式会社 | 網膜組織の製造方法 |
JP2021118733A (ja) * | 2015-09-08 | 2021-08-12 | 大日本住友製薬株式会社 | 網膜組織の製造方法 |
JPWO2017043604A1 (ja) * | 2015-09-08 | 2018-06-28 | 大日本住友製薬株式会社 | 網膜組織の製造方法 |
JPWO2017090741A1 (ja) * | 2015-11-25 | 2018-09-13 | 国立研究開発法人理化学研究所 | 細胞塊に関する領域検出方法及び領域検出装置 |
US10810407B2 (en) | 2015-11-25 | 2020-10-20 | Riken | Region detecting method and region detecting device related to cell aggregation |
WO2017090741A1 (ja) * | 2015-11-25 | 2017-06-01 | 国立研究開発法人理化学研究所 | 細胞塊に関する領域検出方法及び領域検出装置 |
US11371016B2 (en) | 2016-04-22 | 2022-06-28 | Sumitomo Pharma Co., Ltd. | Method for producing retinal tissue |
KR20190082296A (ko) | 2016-11-25 | 2019-07-09 | 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 | 이식용 세포 집단 및 그의 제조 방법 |
WO2018097253A1 (ja) | 2016-11-25 | 2018-05-31 | 国立研究開発法人理化学研究所 | 移植用細胞集団及びその製造方法 |
JP7248246B2 (ja) | 2017-07-20 | 2023-03-29 | 国立研究開発法人理化学研究所 | 神経組織の保存方法 |
JPWO2019017491A1 (ja) * | 2017-07-20 | 2020-06-25 | 国立研究開発法人理化学研究所 | 神経組織の保存方法 |
WO2019017492A1 (ja) | 2017-07-20 | 2019-01-24 | 国立研究開発法人理化学研究所 | 連続的な上皮を含む網膜組織の成熟化方法 |
WO2019017491A1 (ja) | 2017-07-20 | 2019-01-24 | 国立研究開発法人理化学研究所 | 神経組織の保存方法 |
WO2019050015A1 (ja) | 2017-09-08 | 2019-03-14 | 国立研究開発法人理化学研究所 | 網膜組織を含む細胞凝集体及びその製造方法 |
KR20200046088A (ko) | 2017-09-08 | 2020-05-06 | 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 | 망막 조직을 포함하는 세포 응집체 및 그의 제조 방법 |
US11684698B2 (en) | 2017-09-08 | 2023-06-27 | Riken | Cell aggregate including retinal tissue and production method therefor |
WO2019054514A1 (ja) | 2017-09-14 | 2019-03-21 | 国立研究開発法人理化学研究所 | 網膜組織の製造方法 |
WO2019054515A1 (ja) | 2017-09-14 | 2019-03-21 | 国立研究開発法人理化学研究所 | 背側化シグナル伝達物質又は腹側化シグナル伝達物質による錐体視細胞又は桿体視細胞の増加方法 |
WO2020138430A1 (ja) | 2018-12-28 | 2020-07-02 | 国立研究開発法人理化学研究所 | 網膜系細胞又は網膜組織の障害を伴う疾患の治療薬 |
WO2020184720A1 (ja) | 2019-03-13 | 2020-09-17 | 大日本住友製薬株式会社 | 移植用神経網膜の品質を評価する方法及び移植用神経網膜シート |
WO2020218480A1 (ja) | 2019-04-26 | 2020-10-29 | 国立研究開発法人理化学研究所 | 神経網膜と網膜色素上皮細胞とハイドロゲルとを含む複合体及びその製造方法 |
KR20220004097A (ko) | 2019-04-26 | 2022-01-11 | 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 | 신경 망막과 망막 색소 상피 세포와 하이드로겔을 포함하는 복합체 및 그의 제조 방법 |
WO2022054924A1 (ja) | 2020-09-11 | 2022-03-17 | 大日本住友製薬株式会社 | 移植用組織のための媒体 |
WO2022054925A1 (ja) | 2020-09-11 | 2022-03-17 | 国立研究開発法人理化学研究所 | 神経網膜を含む細胞凝集体とマトリクスとを含む複合体及びその製造方法 |
WO2023090427A1 (ja) | 2021-11-19 | 2023-05-25 | 国立研究開発法人理化学研究所 | シート状網膜組織の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
US20220364054A1 (en) | 2022-11-17 |
CN105683366B (zh) | 2020-11-06 |
JP7120585B2 (ja) | 2022-08-17 |
EP3656853A1 (en) | 2020-05-27 |
ES2776707T3 (es) | 2020-07-31 |
JPWO2015025967A1 (ja) | 2017-03-02 |
ES2943670T3 (es) | 2023-06-15 |
SG11201601294PA (en) | 2016-03-30 |
KR102278978B1 (ko) | 2021-07-19 |
EP3037524B1 (en) | 2019-12-11 |
EP3656853B1 (en) | 2023-02-15 |
KR20160045145A (ko) | 2016-04-26 |
JP2022141924A (ja) | 2022-09-29 |
EP3037524A4 (en) | 2017-05-03 |
CA2922079C (en) | 2022-07-05 |
JP6885550B2 (ja) | 2021-06-16 |
US10501724B2 (en) | 2019-12-10 |
JP6580989B2 (ja) | 2019-09-25 |
US20160251616A1 (en) | 2016-09-01 |
CA2922079A1 (en) | 2015-02-26 |
JP2020000248A (ja) | 2020-01-09 |
JP2021118729A (ja) | 2021-08-12 |
CN105683366A (zh) | 2016-06-15 |
AU2014309730A1 (en) | 2016-04-14 |
US20200102535A1 (en) | 2020-04-02 |
EP3037524A1 (en) | 2016-06-29 |
AU2014309730B2 (en) | 2020-11-19 |
JP7435984B2 (ja) | 2024-02-21 |
US11473056B2 (en) | 2022-10-18 |
DK3037524T3 (da) | 2020-03-16 |
EP3037524B8 (en) | 2020-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7435984B2 (ja) | 網膜組織及び網膜関連細胞の製造方法 | |
JP6495176B2 (ja) | 網膜色素上皮細胞の製造方法 | |
KR102111936B1 (ko) | 망막 조직 및 망막 관련 세포의 제조 방법 | |
JP6571533B2 (ja) | 毛様体周縁部幹細胞の製造方法 | |
JP6495830B2 (ja) | 毛様体周縁部様構造体の製造法 | |
JP6393614B2 (ja) | 毛様体周縁部様構造体の製造方法 | |
JP5985209B2 (ja) | 眼杯様構造体の製造方法 | |
JP5985208B2 (ja) | 網膜組織の製造方法 | |
JP6067232B2 (ja) | 網膜層特異的神経細胞を製造する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14838289 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015532926 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2922079 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14913628 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014838289 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20167007728 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014309730 Country of ref document: AU Date of ref document: 20140822 Kind code of ref document: A |